Utah State University

DigitalCommons@USU
All Graduate Theses and Dissertations

Graduate Studies

5-2018

Silane Modulation of Protein Conformation and Self-Assembly
Abul Bashar Mohammad Giasuddin
Utah State University

Follow this and additional works at: https://digitalcommons.usu.edu/etd
Part of the Biological Engineering Commons

Recommended Citation
Giasuddin, Abul Bashar Mohammad, "Silane Modulation of Protein Conformation and Self-Assembly"
(2018). All Graduate Theses and Dissertations. 7029.
https://digitalcommons.usu.edu/etd/7029

This Dissertation is brought to you for free and open
access by the Graduate Studies at
DigitalCommons@USU. It has been accepted for
inclusion in All Graduate Theses and Dissertations by an
authorized administrator of DigitalCommons@USU. For
more information, please contact
digitalcommons@usu.edu.

SILANE MODULATION OF PROTEIN CONFORMATION AND SELF-ASSEMBLY
by
Abul Bashar Mohammad Giasuddin
A dissertation submitted in partial fulfillment
of the requirements for the degree
of
DOCTOR OF PHILOSOPHY
in
Biological Engineering
Approved:
______________________
David W. Britt, Ph.D.
Major Professor

____________________
Jixun Zhan, Ph.D.
Committee Member

______________________
Anhong Zhou, Ph.D.
Committee Member

____________________
Ling Liu, Ph.D.
Committee Member

______________________
Silvana Martini, Ph.D.
Committee Member

____________________
Mark R. McLellan, Ph.D.
Vice President for Research and
Dean of the School of Graduate Studies

UTAH STATE UNIVERSITY
Logan, Utah
2018

ii

Copyright © Abul Bashar Mohammad Giasuddin 2018
All rights reserved

iii
ABSTRACT
Silane modulation of protein conformation and self-assembly
by
Abul Bashar M. Giasuddin, Doctor of Philosophy
Utah State University, 2018
Major Professor: David W. Britt
Department: Biological Engineering
Proteins may self-assemble and form insoluble amyloid-type fibrils, which are
responsible for diseases like Parkinson’s, Huntington’s, Alzheimer’s, spongiform
encephalopathy, and cataracts. Amyloid fibrils are comprised of highly ordered β-sheets
stabilized by an extensive network of intermolecular hydrogen bonds, hydrophobic
surfaces, and favorable packing of side chains. Due to this hierarchical structuring,
amyloid fibrils are resistant to degradation and depolymerization. This research
investigated the use of hydrophobic silane-based polymeric nanoparticles (NPs) to disrupt
fibrillation of a model globular protein, β-lactoglobulin (BLG). After a comprehensive
hydrolysis and condensation study of two hydrophobic silanes, 3,3,3-trifluoropropyl
trimethoxy silane (3F) and n-propyltrimethoxy silane (nPM), nanoparticulate forms of
these silanes were synthesized under mild aqueous conditions and assessed for
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antifibrillation activity. The resulting NPs were superhydrophobic, with water contact
angles on NP films exceeding 150°, suggesting that the fluoro- and methyl-moieties were
accessible on the NP surfaces. Unreacted silanol groups also appeared to be present on
the NP surfaces, as determined from negative zeta potential measurements and infrared
spectroscopy showing OH vibrational bands. Molecular docking of the 3F monomer with
BLG indicated hydrogen bonding of both CF3 and Si-OH moieties with protein residues,
suggesting that an incomplete condensation during NP formation is important for binding
protein, leaving residual silanol groups accessible on the NP surface, in proximity to
fluoro groups.
Under conditions selected to induce BLG fibrillation, the 3F NPs successfully
inhibited fibril formation, resulting in the formation of protein-silane particles rather than
self-assembling into fibrils. Infrared spectroscopy indicated that in the presence of 3F, the
BLG secondary structure was significantly altered. In contrast, the non-fluorinated nPM
NPs failed to inhibit fibrillation under the same conditions, supporting the molecular
docking studies.
The fluoro-silane NPs were further investigated as nano-drug delivery systems.
Quercetin and curcumin, two natural compounds exhibiting anti-amyloid activity, were
successfully loaded into the NPs during the sol-gel synthesis. Rapid and sustained release
profiles were observed for both compounds, supporting applications of 3F NPs as both
active agents and drug delivery systems. The generality of the 3F protein-conformation
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modulating activity was further demonstrated against synthetic spider silk protein, with
the goal of tuning the protein secondary structure to enhance silk fiber properties.
An array of analytical tools, including optical density, dynamic light scattering,
atomic force microscopy, scanning electron microscopy, infrared spectroscopy,
fluorescence spectroscopy, and molecular modeling were employed in these studies to
characterize the NPs and assess their mode of interaction with BLG and synthetic spider
silk. From this research, the hydrolysis and condensation pathways of trifunctional
hydrophobic silane monomers were characterized and optimized, and a new facile onestep and environmentally friendly method for synthesizing superhydrophobic silica NPs
was developed. Applications of the resulting NPs in modulating protein secondary
structure, inhibiting protein self-assembly, and as carriers for hydrophobic drugs were
demonstrated from this research.
(209 pages)
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PUBLIC ABSTRACT
Silane modulation of protein conformation and self-assembly
Abul Bashar M. Giasuddin
This research focused on development of nanoparticle-based therapeutics against
amyloid fibrils. Amyloid fibrils are associated with various diseases such as Parkinson’s,
Huntington’s, mad cow disease, Alzheimer’s, and cataracts. Amyloid fibrils develop
when proteins change their shape from a native form to a pathogenic “misfolded” form.
The misfolded proteins have the ability to recruit more native proteins into the pathogenic
forms, which self-assemble into amyloid fibrils that are hallmarks of the various proteinmisfolding diseases listed above. Amyloid fibrils are highly resistant to degradation,
which may contribute to the symptoms of amyloid diseases. Synthetic drugs, natural
compounds, and antibodies are widely explored for potential to stop pathogenic protein
assembly or to promote fibril degradation and clearance, but to date have had little
success in relieving symptoms in clinical trials. In this research, I have synthesized
fluorine-containing silica nanoparticles (NPs), and tested their fibril-inhibiting activity
against amyloid fibrils formed by a non-pathogenic protein, β-lactoglobulin (BLG).
These fluoro-silica NPs prevented BLG amyloid formation, whereas non-fluorinated
nanoparticle analogs did not inhibit fibrillation under the same reaction conditions. The
fluoro-silica NPs interacted with the BLG protein in a manner that prevented the protein
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from adopting a form that could self-assemble into fibrils. Additional applications of the
NPs were explored as small-molecule drug-delivery systems; such that multiple
functionalities could be introduced into a single nano-therapeutic.
Abul Bashar Mohammad Giasuddin
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CHAPTER 1
AMYLOIDOSIS DISEASE, SILANE-INDUCED PROTEIN CONFORMATION
CHANGE AND SELF-ASSEMBLY

1.1 Background and literature

1.1.1 Protein and its folding mechanism
Proteins are among the most complex and diverse bio-macromolecules, comprised
of 20 amino acid residues linked into linear chains by peptide bonds. Proteins have four
layers of structure, which hierarchically define the protein folding process. The linear
sequence of amino acids forms the primary structure of the protein. An extended linear
chain, however, is energetically unfavorable, and the polypeptide will explore
conformations that reduce the net free energy and solvent exposure. Hydrophobic amino
acids sequester to minimize contact with aqueous solvents, and a random coil type
structure can be expected as a result. However, the primary structure of a protein predetermines the types of interactions that will be favored as the chain undergoes random
fluctuations, thus directing the folding of the polypeptide and resulting in the formation
of secondary structure elements such as α-helices and β-sheets.
The α-helix is a common protein secondary structure motif and is a coiled or
spiral conformation in which hydrogen bonds are formed between backbone carbonyl
(C=O) and amine groups (N-H) that are separated by a distance of four residues.
Backbone hydrogen bonds also stabilize another type of secondary structure in proteins,
called the β-sheet. In β-sheet motifs, a planar structure is stabilized as hydrogen bonds are
formed at regular intervals between residues as the peptide chain folds upon itself in a
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lamellar pattern. The β-sheet is defined by the lamellar folds in the backbone; each fold is
termed a β-strand, and neighboring strands are connected laterally by at least two or three
backbone hydrogen bonds resulting in a pleated sheet. The β-strand is typically 3 to
10 amino acids long with the backbone arranged in a linear, extended conformation. βsheets are termed either parallel or anti-parallel, depending on whether the β-strands are
oriented in the same backbone (C to N : C to N) direction, or opposite directions (C to N :
N to C). These structures are of key importance in protein-misfolding diseases, where
pathogenic protein isoforms that are rich in β-sheets recruit native isoforms by inducing a
net transition from α-helix to β-sheet. In these proteins, the β-sheets exhibit a propensity
to inter-molecularly self-assemble into fibrils and amyloid plaques. Experimentally, the
switch in protein conformation is easily triggered by a number of factors such as heat,
low pH, H-bond disrupting solvents, and interactions with surfaces and nanoparticles
(NPs). β-sheet assembly is also a key process in formation of non-pathogenic protein
macro-structures, such as collagen and spider silk fibers.
While β-sheets are necessary for inter-protein assembly into fibrils, there are
many β-sheet-rich proteins that do not assemble into fibrils. This is due in part to the
protein tertiary structure, where α-helices and β-sheets are arranged in a stable threedimensional structure that defines the native state. The tertiary structure of protein
involves global interactions arising from hydrogen bonds, ionic bonds, hydrophobic
interactions, and disulfide bonds. In contrast to the secondary structural motifs involving
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H-bonding between backbone amide groups, these interactions occur between the side
(R) groups of the amino acids, holding the secondary structures in defined arrangements
that form the tertiary structure. These interactions may be physical bonds, such as Hbonds and salt bridges, or covalent bonds in the case of disulfide bonds between cysteine
residues in close proximity.
The final level of protein structure is the quaternary structure, which is the
assembly of multiple individual polypeptide or protein chains into a multi-subunit
protein. Intermolecular interactions hold the substituent polypeptide or protein chains into
a functional geometry, often stabilized by disulfide bonds. Protein quaternary structure is
grouped into the two major categories of “fibrous” and “globular”. Globular proteins may
contain helical, pleated or random chain structures, and are relatively spherical in shape.
Some examples of globular proteins are hemoglobin, myoglobin, insulin, and egg
albumin. Collagen, silk, and keratin are common examples of fibrous protein structures.
Amyloid fibrils are examples of fibrous structures associated with disease. In both native
and pathogenic cases, quaternary structure is a supramolecular geometry that emerges
from the hierarchical assembly of building blocks following defined rules for assembly.
During protein synthesis, the disordered polypeptide arranges into the ordered
native state through the process of protein folding. Most proteins spontaneously fold into
a specific conformation, driven by the hydrophobic effect and stabilized through
chemical bonds and physical interactions that form secondary, tertiary and quaternary
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protein structures. Proteins known as chaperones may also guide the folding of newly
synthesized proteins into the correct geometry corresponding to the functional
conformation. Chaperones are also involved in the re-folding of proteins following heat
shock or other stress.
The correct folding of a protein is essential to function, whether structural,
enzymatic, signaling, or transport. The unfolded or denatured state of a protein is
considered to be an ensemble of structures ranging from fully disordered random coils, to
relatively well-defined molten globule conformations. (1) The molten globule state is
distinct from the globular quaternary structure. A schematic of unfolded and folded
protein structures is shown in Figure 1-1.

Figure 1-1. Schematic of protein folding. (Adapted from (2))
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Generally, a globular protein folds in such a way that it contains a hydrophobic
core surrounded by a hydrophilic outer layer. This promotes the formation of a dense,
compact structure. The exposure of hydrophobic residues to a polar solvent such as water
is energetically unfavorable as it results in water adopting an organized “ice-like” layer or
clathrate around these residues. (3) The entropic penalty for these water molecules favors
protein folding to sequester hydrophobic residues together in the protein interior, which is
free from solvent. This is known as the “hydrophobic interaction”, and it is primarily
driven by an entropy gain as organized water molecules are liberated from the
hydrophobic residues during the folding process. Hydrogen bonds, Van der Waals
interactions, and salt bridges stabilize the secondary, tertiary, and quaternary levels of
structure that, in concert, stabilize the net structure. In this manner, weak forces act
together to contribute toward a stable and functional protein conformation.
Protein folding is reversible, and metastable conformations may also be adopted
during folding or unfolding. (4) To spontaneously adopt the folded or native state, a
protein folding pathway must be a thermodynamically favorable process. Energy
diagrams identify the most stable form or minimum energy condition of a protein. (5)
Under physiological conditions, the native or folded state of a protein contains lower free
energy compared to the unfolded state. (6) The free energy difference, DG, which is
defined as DH-TDS (DH and DS are the enthalpic and the entropic changes, respectively),
can be used to explain this phenomenon. To reach a stable folded state, a favorable

6
enthalpy change arising from numerous interactions (hydrophobic, electrostatic,
hydrogen bonding) drives the reaction. This is, however, opposed by the entropy decrease
associated with the folded state, because it requires a large number of unstructured
conformations to be turned into a single ordered structure to achieve this state. The net
entropy change, however, is favorable as entropically unfavorable water clathrates
surrounding exposed hydrophobic residues are liberated as disordered bulk water upon
folding of the protein.
In this manner, the system overcomes the penalty associated with the polypeptide
chain conformational entropy decrease to reach its folded state. The role of the solvent in
protein folding and unfolding is important and will be revisited in the discussion of the
influence of solvents, such as fluoroalcohols, on protein secondary structure. As proteins
vary widely in size, structure, and function, the enthalpy and entropy changes associated
with denaturation vary respectively; nevertheless, the free energy changes of most
proteins are generally confined to a narrow range (5-15 kcal/mol). (7) The contribution of
these individual interactions to the total free energy change can be estimated using highly
sensitive calorimetric methods. As these energy values are relatively low, minor changes
in solution pH, ionic strength, and temperature can lead to protein destabilization and the
adoption of meta-stable conformations such as the molten globule state, as depicted in the
energy diagram Figure 1-2.
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Figure 1-2. Energy diagram of protein folding. (Adapted from (5))
The perturbed structure may further denature, refold, or under certain conditions, selfassemble into supramolecular structures such as amyloid fibrils.
The early view of the protein folding was based on kinetics models, which were
derived from simple or multiple exponential time decays of optical properties paralleling
changes in protein structures upon initiation of folding. More extensive work was then
carried out to identify stable intermediates, corresponding to molten globule states, now
known to define the pathways of folding, as depicted in Figure 1-3. The molten globule
has most of the secondary structure of the native state and in some cases even native-like
positions of the α-helices and β-strands. It is less compact than the native structure, and
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the proper packing interactions in the interior of the protein are not formed. Also, loops
and other elements of surface structure remain largely unfolded, adopting conformations
distinct from the native folded structure.

Figure 1-3. Molten globule state of protein.
The molten globule is not viewed as a single structural entity but as an ensemble
of related structures that are rapidly inter-converting. It is a major challenge to conceive a
single mechanism, which would satisfactorily explain (as well as predict) the folding of
all proteins. From empirical studies and computational predictions, a number of models
have been developed to describe the pathways and intermediates associated with protein
folding, which have led to three classical mechanisms of protein folding that are
illustrated in Figure 1-4. (8)
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Figure 1-4. Schematic of protein folding mechanism. (Adapted from (8))
Nucleation-growth model: This model proposes the initial formation of a local
element of secondary structure from which a tertiary structure propagates rapidly. This
pathway ignores the possible transition through any molten globule intermediates, which
are often experimentally observed during the protein folding process.
The hydrophobic collapse model: According to this model, during the folding
process, hydrophobic amino acids collapse and form a compact structure by excluding
water. Unlike the nucleation-growth model, this model describes the formation of molten
globule intermediates that arise from the collapse of the hydrophobic amino acids prior to
reaching the native conformation. However, a non-specific hydrophobic collapse process
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that results in a highly stable intermediate may significantly impede reorganization of the
polypeptide into the final native state.
The hierarchical model: This model describes a stepwise process where all of
the secondary structural elements such as helices, turns, and sheets are first folded to
yield a hierarchy of stabilized secondary structures, which have fewer degrees of spatial
freedom as they explore intramolecular interactions that lead to the native folded state of
the protein.

1.1.2 Amyloid, self-assembly, and conformational disease
The ability of proteins to fold into a defined and functional conformation is one of
the most fundamental processes in biology. However, several diseases arise from the
misfolding, or partial unfolding, of proteins, which have implications beyond a mere loss
of functionality, as the misfolded proteins may self-assemble and aggregate into a
quaternary structure identified by insoluble plaques. In Alzheimer’s disease (AD), the
amyloid hypothesis links neurodegeneration and diminished cognition to the amyloid
plaques comprised of ab42 proteins. Thus, therapeutics that target plaques have been
widely explored, but with limited clinical trial success. Due to these poor clinical trial
outcomes of therapeutics designed to clear amyloid from patients, the central hypothesis
that symptoms are a direct result of plaque formation is coming under increasing scrutiny.
(9) Trials exploring early administration of amyloid inhibitors for patients at risk for AD
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may provide additional insight into the relation between amyloid fibrils and disease
symptoms.
Specific intermolecular interactions between hydrophobic residues forming
structural subunits in partially folded or unfolded intermediates prime the formation of
amyloid plaques and fibers, as a loop in the protein chain is converted to a β-strand. (10)
For example, in spongiform encephalopathies, cellular prion PrPc converts to the
pathogenic isoform PrPsc with an associated decrease of α-helical content (from 42 % to
30 %) and increase in β-sheet structure (from 3 % to 43 %). (11, 12) The pathogenesis
arising from the assembly of β-sheet structures into amyloid is contrasted with the
assembly of native proteins rich in β-sheet, such as spider silk proteins where the strength
and water solubility of the bio-fiber produced from protein depends on the crystallinity of
β-sheet structure. (13) Thus, from a fundamental assessment of protein hierarchical
assembly, external agents that promote fibrillation are also of significant interest.
Although certain conditions allow the supramolecular assemblies of β-sheet rich
proteins to be reversed, in most cases the aggregation process is irreversible. Genetic
defects and mutation can destabilize the native state of the protein and eventually
promote the aggregation of the protein. Adverse cellular and physiological factors and
post-translational processes also can promote aggregation of protein. (14)
Among the cellular conditions, elevated temperature is a key element in protein
aggregation. (7) Heat can disrupt the hydrogen bonds that dictate folding, while changing

12
the pH of the protein's environment can affect ionic bonds, and reducing agents can
cleave any disulfide bonds stabilizing the tertiary and quaternary structures. Oxidative
stress has also been shown to contribute to the pathogenesis of many protein aggregation
processes. (15) Additional determining factors are ionic strength, chaotropic agents, cosolutes, and the presence or absence of various molecular chaperones.
A wide number of experimental conditions may induce amyloid, and in most
instances the misfolded proteins form fibrils that have a commonality of being rich in βsheet conformations. In-vivo, the organized oligomerization of misfolded protein into βsheet rich conformations can lead to the production of the characteristic amyloid plaque,
which is described as extracellular, fibrillar protein deposits associated with diseases in
humans. (16) Clearly not all proteins rich in β-sheet conformations spontaneously selfassemble into supramolecular structures. This level of assembly is generally strictly
controlled, as in the case of proteins involved in structural roles, such as collagen fibers.
The β-sheet assembly in pathogenic proteins presents a challenging problem that can be
addressed by understanding the intermediates, such as the molten globule, involved in the
transition from a non-pathogenic isoform to a pathogenic one. Figure 1-5 shows a
schematic of amyloid fibril formation that describes fibrillation pathways involving the
molten globule intermediate. (17)
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Figure 1-5. Schematic of amyloid fibril formation. (Adapted from (17))
Amyloid-based diseases involve recruitment and self-assembly of proteins into
insoluble fibrils and plaques, leading to a variety of pathologies, including Alzheimer’s,
Parkinson’s, cataracts, dialysis-related amyloidosis, and type II diabetes in humans, and
spongiform encephalopathy in cattle, sheep, and elk. (18) Figure 1-6 presents a schematic
of different amyloidosis diseases and their protein aggregation and misfolding patterns.
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Figure 1-6. Schematic of amyloidosis diseases with the corresponding proteins and their
abnormal transformational changes. (Adapted from (18))
1.1.3 Solvent, surface, and nanoparticle-induced protein conformations
Currently no therapeutic is available to prevent or treat amyloidosis diseases.
Several therapeutics have shown success in-vitro and in animal models, but have failed to
halt disease progression or reduce symptoms in clinical trials (16). Proposed amyloid
aggregation or fibrillation inhibitors can be categorized in three groups: 1) protein /
peptides, 2) small molecules / colloid, and 3) organic / inorganic NPs. An overview of
compounds exhibiting anti-fibrillation activity is compiled in Table 1-1.

15
Table 1-1. Overview of compounds that exhibit fibril inhibition activities.
Protein type

Fibril inhibitor

αβ13-28
BACE1
HEWL
Αβ1-42
BLG
αβ2M
BLG
BLG
αβ1-42
Human Insulin
αβ1-42

Solanezumab (monoclonal antibody)
Veruvecestat (beta-secretase inhibitor)
Myricetin (flavonoid)
Aducanumab (monoclonal antibody)
Folic acid (B-vitamin)
SDS (anionic surfactant)
Au NPs
Fe3+
Histidine coated Au NPs
Carbon dots
Tabersonine (terpene indole alkaloid)

References
19
20
21
22
23
24
25
26
27
28
29

In many of the studies it has been noted that polymeric and inorganic NPs have been
reported to accelerate or promote the protein fibrillation. Fibrillation promoters are listed
in Table 1-2.

Table 1-2. Overview of compounds that have been reported to exhibit fibril promoting
activities.
Protein type

Fibril promoter

HSA
αβ peptide
αβ42
Human β2m
Amyloid β

Cu2+
(PEI-P) conjugates
TiO2
NIPAM / BAM NPs
Polystyrene NPs

References
30
31
32
33
34
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Alcohols have been widely characterized for their roles in inducing protein
secondary structures. (35) Alcohol co-solvents are widely used to denature proteins and to
stabilize induced secondary structures in peptides. The ability of aliphatic alcohols to
denature proteins increases with their effective methylene chain length (i.e. pentanol >
butanol > propanol > isopropanol). (36) Among the alcohols, fluoro-substituted alcohols
such as TFE (2,2,2-trifluoroethanol) and HFIP (hexafluoro-2-propanol) have been found
to be more effective co-solvents for evoking structural changes in protein and peptides
compared to aliphatic-alcohols. (37) HFIP and TFE partially denature protein native
structures and induce α-helices in numerous proteins and their fragments. This secondary
structure selective activity leads to their investigation as solvents for transforming
proteins into molten globule intermediates, stabilizing induced intermediates, or
dissolving aggregates. As discussed earlier, the thermodynamics of protein folding and
stability hinges on the properties of the water solvent. Disruption of organized “ice-like”
water on a protein surface by a co-solvent, such as a fluoroalcohol, increases the water
entropy, but also will reduce the enthalpy associated with these surface bound water
molecules. This in turn may promote the adoption of new secondary structural motifs, in
particular, α-helices. Table 1-3 presents those proteins whose conformations have been
investigated against fluoro-alcohols.
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Table 1-3. Overview of fluoro-alcohol-protein studies investigating secondary structure
changes in proteins and peptides. (Adapted from Y. Peng Ph.D. thesis, Utah State
University, 2011. (53))
Protein type
Silk model peptide
Octapeptide
Alzheimer’s beta-peptide
Nα-acylated heptapeptide amide
Islet amyloid polypeptide
22-residue peptide of macroglobulin
Papain
Succinylated Con A
Pea lectin
β-lactoglobulin
Tau protein
Bovine serum albumin
Barstar
Cytochrome c
Acylphosphatase

Inducer fluoro-alcohol
HFIP
HFIP, TFE
HFIP
HFIP
HFIP, TFE
HFIP, TFE
HFIP, TFE
HFIP, TFE
HFIP
HFIP, TFE
TFE
TFE
HFIP, TFE
HFIP
TFE

References
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

HFIP, and TFE at higher concentrations, are able to dissolve protein aggregates.
However, at lower concentrations these fluoro-alcohols may actually promote β-sheet
structures and form amyloid fibril in several models. (54) It has been reported that αchymotrypsin, an all β-sheet protein, aggregated into amyloid-like structures in the
presence of TFE, where the maximal amount of fibrillar aggregation was formed at 35 %
(v/v) TFE. (55) As the TFE concentration was increased to above 40 % (v/v), the
aggregation propensity was reduced. When HFIP was used, β-sheet conformations were
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maintained in 3 % or below HFIP-water mixtures (v/v), while the formation of α-helices
was observed when HFIP content was increased over 20 %. (54, 56)
During the interaction with a polypeptide, HFIP and TFE can each simultaneously
act as a proton donor and acceptor due to the presence of highly electronegative fluorine
and alcohol groups. The fluorine acts as a hydrogen acceptor and forms H-bonds with the
proton donor groups on the protein. The fluoro-alcohol hydroxyl group is a very strong
proton donor and selectively binds with the protein backbone carbonyl group. (37)
Through this fluoro-alcohol-peptide interaction, the solvent exposure of the backbone
amide is reduced and intra-polypeptide hydrogen bonding of the amide group is favored,
which increases the helical propensities.
The hydrophobic properties of alcohols are very influential to their activities on
polypeptide structures. The longer chain aliphatic n-alcohols, such as propanol or butanol
are much more potent than methanol. (37) The presence of –CF3 in HFIP and TFE makes
both the fluoro-alcohols highly efficient inducers on the structural transitions of protein.
The presence of hydrocarbon groups and multiple fluorine atoms increases the
hydrophobicity of the fluoro-alcohol, which can play a vital role in denaturing protein
secondary structures and inducing the formation of helical structures. (37, 58) HFIP and
TFE both have a high tendency to self-aggregate to form micelle-like assemblies in
aqueous solution. Aggregation of HFIP and TFE in water produce clusters with a Stokes
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radius of about 24 Å, and 6 Å, respectively and these clusters further reduce solvent
polarity around the protein. (59-62)
The electronegativity of fluorine in alcohols increases the polarization of the
terminal hydroxyl groups, which consequently leads to enhanced H-bond donor activity
(62, 63), resulting in the enhanced effects of HFIP and TFE, as compared to analogous
organic alcohols. Thus, the fluoro-alcohols interact with protein both as hydrogen bond
donors and acceptors, whose bindings are further stabilized by hydrophobic interactions.
HFIP has a higher inducing capacity on protein secondary structures compared to TFE,
due to its stronger hydrophobicity – greater H-donor and H-acceptor activities associated
with incorporation of multiple F atoms – which also promotes the higher tendency of
HFIP to aggregate into nano-structures that may form multi-valent interactions with
proteins.
Although HFIP and TFE are model compounds for inducing protein structural
transitions, both are highly corrosive, toxic, and flammable. These properties preclude
their use as therapeutic agents for amyloid diseases, as well as limit bioprocessing
applications to promote protein-based fiber assembly. Alternatively, polymerizable
silanes analogous to HFIP and TFE could be applied to produce therapeutic polymers,
NPs, or protein-silane hybrids that exhibit favorable properties associated with HFIP and
TFE, without the negative aspects. For example, hydrophobic alkoxysilanes are widely
used as coupling agents to modify surfaces, forming porous gels, and to construct NPs.
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Protein encapsulation in porous sol-gel glasses has been widely used in heterogeneous
bio-catalysis applications and in the development of solid state optical and
electrochemical biosensors. (64-64) Sol-gel glass encapsulation has been demonstrated to
retain the activity of a wide variety of enzymes.
Recently, hydrolyzable hydrophobic fluoro-silanes analogous to TFE or HFIP
have been studied for their protein structure inducing ability at acidic pH. (53, 67) These
studies showed that 3,3,3-trifluoropropyl trimethoxy silane (3F), which is analogous in
structure to TFE and nPM (n-propyltrimethoxy silane) – a non-fluorinated analog of 3F –
are both strong protein secondary structure inducers that are also polymerizable. Circular
dichroism analysis of protein structure in the presence of hydrolyzed 3F and nPM (H3F,
HnPM, respectively) demonstrated the conversion of β-sheet structures into α-helices.
(67) These findings lead to the central hypothesis of this research.

1.1.4 Hypothesis
Polymeric nanoparticles (NPs) of hydrophobic alkoxy- and fluoro- silanes induce
defined changes in the secondary structures of protein, which depending on the NP
concentrations and surface properties, can be used to inhibit or promote protein
fibrillation in aqueous media.
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1.2 Objectives
Building on earlier works (53, 67), which demonstrated that at low pH,
hydrolyzed nPM and 3F induced β-sheet to α-helices, this work aims to identify
underlying mechanisms and expand applicability. The key objectives of this research are
to:
1. Understand the hydrolysis and condensation behavior of 3F and nPM in aqueous
solution catalyzed at select acidic pH values.
2. Characterize the physical and chemical properties of the polymeric particles as
they develop during the condensation process.
3. Determine whether fluorinated and methylated polymeric nanoparticles, like their
hydrolyzed precursor monomers, inhibit amyloid fibrillation of a model protein.
4. Assess the types of conformational changes in the model protein during the
inhibition process.
5. Model the interaction between polymeric NPs and protein using Molecular
Docking models of protein with hydrolyzed silane monomers.
6. Develop superhydrophobic NPs from the hydrolyzed 3F and nPM, following
conventional condensation methods, and determine the efficiency of these NPs as
amyloid inhibitor and as carriers for hydrophobic drug molecules.
7. Determine the modulating ability of 3F and nPM against the secondary structures
of spider silk proteins.
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1.3 Research methods overview
The experimental approach to addressing the objectives and answering the central
hypothesis is outlined in the research flow chart in Figure 1-7. A variety of
complementary techniques and instruments are applied to address the hypothesis and
questions associated with hydrophobic silane assembly to form nanoparticles that modify
protein secondary structures, and propensity to assembly into supramolecular
architectures, such as fibrils and sheets.

Figure 1-7. Research flow chart illustrating the major directions and methods.
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CHAPTER 2
HYDROLYSIS AND CONDENSATION OF HYDROPHOBIC SILANES IN
AQUEOUS SOLUTION

2.1 Abstract
The hydrolysis and condensation pathways of 3,3,3-trifluoropropyl trimethoxy
silane (3F) and n-propyltrimethoxy silane (nPM) were investigated over an acidic pH
range, to identify conditions yielding stable hydrolyzed silane monomers to be tested for
protein conformation-inducing activity, as both hydrolyzed monomer and when
condensed into nanoparticles (NPs). The reaction kinetics were assessed through turbidity
measurements and dynamic light scattering (DLS) in aqueous solutions at pH 1.7, 2.0,
2.5, and 3.0. Prior to hydrolysis, 3F and nPM are insoluble in water and form a lens at the
bottom of the aqueous solution for 3F, and on the top of the solution for nPM. As the
silanes underwent hydrolysis, they became soluble in the aqueous phase at a rate that
increased with decreasing pH, with the fluorine-based silane (3F) exhibiting slower rates
compared to the non-fluorinated structural analog (nPM). DLS analysis revealed that at
pH 1.7 and 25°C, NP growth from the hydrolyzed nPM and 3F silane precursors at 0.4 M
was detected at 80 min and 175 min, respectively, and rapid growth / aggregation resulted
in NPs >1 µm after 160 min for nPM, and 375 min for 3F. AFM analysis of these NPs
confirmed the NP sizes observed in the DLS study. ATR-FTIR was employed to monitor
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the chemical composition during the hydrolysis and condensation, as vibration bands for
Si-OH and Si-O-Si bonds appeared, respectively. Zeta potential characterization revealed
that at pH 1.7 and 3.0, both nPM and 3F polymeric NPs had negative surface charges.
The negative surface charges on the NPs were attributed to the presence of surface
accessible Si-OH groups, despite an overall hydrophobic character, as measured by water
contact angle. The presence of hydrophobic and silanol moieties implies an amphipathic
surface character on these NPs, which, based on prior analyses of silane monomer
interactions with proteins, make these NPs potential candidates against protein
conformational diseases.

2.2 Introduction
Functional di- and tri-alkoxysilanes (e.g. silanes with two and three reactive
leaving groups, respectively) are used for various applications such as adhesion
promoters and cross-linkers between a polymer matrix and inorganic solids, as resin
precursors, as agents to modify surface properties, and to form porous matrices to capture
and encapsulate biological molecules. (1) Alkoxysilanes react slowly, compared to the
corresponding chlorosilanes, and are preferred over chlorosilanes for the reactions
involving biological molecules, because they liberate organoalcohols, compared to the
hydrochloric acid released by chlorosilanes during hydrolysis. The hydrolysis and
condensation reaction rates of alkoxysilane decrease with the bulkiness of the alkoxy-
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leaving group. Methoxy and ethoxy moieties are the two most common leaving groups,
and during the hydrolysis, they are liberated as methanol and ethanol, respectively. The
hydrophobicity of these groups render the silane insoluble in aqueous solution, unless a
polar functional group is also present; the n-propyl chain of nPM and tri-fluoro moieties
of 3F prevent solubilization of these monomers until hydrolysis begins. Alkoxysilane
undergoes serial hydrolysis of the alkoxy leaving groups, rendering the silane reactive
through the resulting silanol (Si-OH) functionalities. Silanol reactivity enables silanes to
be anchored to oxidized surfaces, as well as other silanes bearing alkoxy or hydroxyl
groups. Silicon is tetravalent, thus a tri-alkoxysilane contains an additional moiety, R’,
which may impart functionality to the silane, such as ability to interact with an organic
matrix or influence biological molecule binding by modifying the surface energy and
hence the interfacial adhesion behavior. This R’ moiety can have a range of
functionalities, such as epoxy, acrylate, amino, fluoro etc., as well as simple alkyl or aryl
groups. A confluent layer of silanes anchored to an oxidized surface may dramatically
change the interfacial energy, depending on the R’ group chemistry. For fluoro and alkylsilane coatings, the R’ moieties render the surface hydrophobic.
While hydrolyzed silanes readily condense to form silanol (Si-O-Si) bonds with
free hydroxyl groups on material surfaces, biomolecules such as proteins, and with other
hydrolyzed silanes; they also readily form physical bonds, such as acid-base interactions,
hydrogen bonds, dipole-dipole interactions, and van der Waals interactions. (2) Tri-
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alkoxy silanes with their R’ moiety having hydrophobic functionality can also interact
through hydrophobic interactions, which, in the case of alkyl chains, imparts a strong
amphiphilic character to the silanes that drives silane self-assembly on surfaces. The
hydrolyzed silane monomer is generally regarded as an intermediate to forming a
condensed silane product, in the form of a thin film, nanoparticle, or matrix. However,
for certain silanes, the hydrolyzed monomer is of interest as a biologically active small
molecule. For trifunctional silanes where the R’ group is a short chain alkyl- or fluorogroup, the resulting hydrolyzed silane monomer has been shown to interact with proteins
and induce conformational changes that exceed the conformation-inducing activities of
organo- and fluoro-alcohols. (3) The general applications of tri-alkoxysilane depend on
the hydrolysis of the ºSiOR’ groups to produce silanols, which ultimately condense to
siloxanes and polysiloxanes. However, partially hydrolyzed and partially condensed trialkoxysilanes containing silanols and organosiloxanols can exhibit unique properties to
be applied as therapeutics, due to their polymeric nanoparticulate nature. (4)
Most studies on the hydrolysis and condensation kinetics of alkoxysilanes were
performed in either organic or organic and aqueous mixed solvents. (5-15) The general
reaction steps in the hydrolysis and condensation of tri-alkoxysilanes can be written as:
R’Si(OR)3 + nH2O

R’Si(OR)3-n(OH)n + nROH

Hydrolysis

R’Si-OR + HO-SiR’

R’Si-O-SiR’ + ROH

Condensation

R’Si-OH + HO-SiR’

R’Si-O-SiR’ + H2O

Condensation
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For the effective biological applications of hydrolyzed or partially condensed
silanes, the hydrolysis and condensation must be performed in aqueous, biologically
relevant solutions. Moreover, for the biological applications of these silane compounds, a
nontoxic solvent is essential. The key factors on which this hydrolysis and condensation
process in aqueous solution depends are pH, type of R’ functionality, size and type of
alkoxy group, catalyst, and the concentration of the silanes in the solutions. (6) Two types
of catalysts are used for the hydrolysis and condensation of alkoxysilanes, namely acid
and base, with distinct pathways and kinetics observed for each. Of particular relevance
to NP formation, the condensation process is favored in basic solutions.

Figure 2-1. Schematic of the reaction scheme of hydrolysis and condensation kinetics of
tri-alkoxysilanes at acidic and basic conditions in aqueous media, along with a numerical
reaction scheme. (Adapted from (7))
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Figure 2-1 is a schematic of the hydrolysis and condensation pathways as they occur in
either acidic or basic solutions, along with a numerical representation of the reaction
scheme. For acidic pH, hydrolysis is favored over condensation, while in basic pH,
condensation occurs more readily than hydrolysis. Acid catalysis favors hydrolysis that
follows a sequential displacement of –O-CH3 with –OH; and when all three –O-CH3 are
replaced with –OH, the silane is in a fully hydrolyzed state, which can be achieved before
condensation begins.
A previous study from our lab showed that hydrolyzed 3F and nPM could highly
induce the secondary structures of model proteins, with the three silanols playing a major
role in this conformation-inducing activity through strong H-bond donor activity. (16) It
is intuitive that as more silanols are present, greater hydrogen bonding is possible, and
stronger biomolecular interactions are likely. Thus, for silane-induction of protein
conformation, it is desirable to maintain at least a partially hydrolyzed state and thus
employ an acid catalyst.
Although several studies have been published on the hydrolysis and condensation
kinetics of tri-alkoxysilanes in aqueous or aqueous-organic mixed solutions, there are no
reports available on the evolution of the polymeric particles generated during the
condensation of tri-alkoxysilanes following the hydrolysis step in acidic aqueous
solution. It is very important to have a clear understanding of the evolution of the size of
the polymeric particles during the condensation of the tri-alkoxysilanes, especially when
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particles are to be used in biomolecular applications. Linear condensation products from
tri-alkoxy silanes will contain silanol functionalities that are stable after condensation is
complete, providing H-bond donor functionality to these polymer chains as well as NPs
that result from these chains.
Various techniques and analytical tools have been used to investigate silane
hydrolysis and condensation kinetics such as NMR, FTIR, Raman spectroscopy,
chromatography, mass spectroscopy, and X-ray scattering. (17-33) Of these methods, 29Si
NMR spectroscopy has been found to be a powerful tool to follow evolution of
intermediates and final products, because this spectroscopy can differentiate silicon
atoms attached to different chemical groups. The limitation of this instrument is the low
gyromagnetic ratio and long relaxation time, which is unsuitable for studying some rapid
hydrolysis reactions in real time, like hydrolysis and condensation of di and trialkoxysilanes at lower pH. In situ Attenuated Total Reflectance-Fourier Transform
Infrared (ATR-FTIR) spectroscopy was successfully used in quantitative analyses of
hydrolysis and condensation of TEOS at lower pH, where spectra measured at different
time periods showed that TEOS was first converted into ethanol and Si(OH)4 and then
precipitated as amorphous SiO2. (34) Riegel et al. used Fourier Transform Raman spectra
with laser excitation in the near IR during base-catalyzed sol-gel reaction of GPTS (3glycidoxypropyltrimethoxysilane) and APTS (3-aminopropyltriethoxysilane) where
Raman bands of the tri-methoxysilyl and epoxy moieties were used to monitor the kinetic
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behavior of the hydrolysis and the ring cleavage as a function of temperature. (25) Pelster
et al. used electrospray mass spectrometry to observe pre-nucleation reactions of silicates
from an aqueous solution containing TAAOH (tetraalkylammoniumhydroxides) and
TAOS (tetraalkoxysilanes). Their study showed the evolution of different silicate species
occurring during the condensation process. Their time-resolved measurements were done
in a stepwise hydrolysis, and subsequent condensation of silicate monomers via
oligomers to form larger units. (30)
All of the above-mentioned techniques were used only to identify the hydrolyzed
and condensed products, and not the evolution of condensation product size, morphology,
and surface characteristics. DLS is commonly used to measure the hydrodynamic size of
organic and inorganic nanoparticulates in solution. (35) Turbiscan is an advanced optical
absorbance / transmission technique widely used in the food industries. Turbiscan is
operated based on the turbidity in the solution caused by scattered light from foams,
emulsions, or particles. (36)
Here, we have reported the hydrolysis and condensation kinetics of two
hydrophobic alkyl- tri-alkoxy and fluoro- tri-alkoxy silanes in aqueous solution analyzed
by DLS and Turbiscan. Evolution of the polymeric NPs during the condensation was
quantitatively analyzed by DLS, and resulting particle charge and morphologies assessed
using zeta potential and AFM, respectively. FTIR was employed to identify chemical
groups present on the NP products.
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2.3 Experimental Section
Source of chemicals
Double Distilled Deionized (DI) water was collected from BarnsteadTM
MegaPureTM Glass Still (Thermo Scientific); Hydrochloric Acid (HCl) 1.0 N was
purchased from Ricca Chemical Company (Arlington, TX); 3,3,3-trifluoropropyl
trimethoxy silane (3F, > 95 % purity, MW= 218.3, d = 1.14 g/ml), and npropyltrimethoxy silane (nPM, > 95 % purity, MW= 164.3, d = 0.94 g/ml) was purchased
from Gelest, Inc. (Morrisville, PA); and Potassium Chloride (KCl) was purchased from
Thermo Fisher Scientific, NJ.
Monitoring reaction time through silane phase
Four different 0.4 M solutions were prepared for both nPM and 3F at pH 1.7, 2.0,
2.5, and 3.0 using 20 mM, 10 mM, 5 mM, and 1mM HCl solution respectively. The
hydrolysis and condensation were monitored using a Nikon COOLPIX P510 camera.
Turbiscan Analysis
Hydrolysis and condensation behavior of nPM (0.4 M) and 3F (0.4 M) at pH 1.7,
2.0, 3.0, and 4.0 were followed by measuring the transmissivity of light (850 nm) through
the samples using a Turbiscan instrument (Turbiscan Classic, MA200, L’Union, France),
and data were analyzed using Turbisoft 1.2.1. All solutions were prepared as described
above, and the pH 4.0 solution was 0.1 mM HCl. All solutions were placed in the
Turbiscan tubes to a height of 35±0.5 mm, and transmissivity was measured as a function
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of time. Transmissivity was measured throughout the height of the solution in the tubes
for 12 to 96 h, and measurements were taken at 2 to 22 min intervals, depending on the
pH of the solutions, which influenced reaction rates. Data were plotted using Sigma Plot.
Dynamic Light Scattering (DLS) analysis
Evolution of polymeric NPs during nPM and 3F hydrolysis and condensation
were analyzed by DLS (DynaPro NanoStar, Wyatt Technology Corporation, Santa
Barbara, CA), with a 658 nm laser. Measurements were taken using a quartz cuvette (JC426, 1 µl) with 0.7 ml of nPM (0.1 M) and 3F (0.1 M) solution at pH 1.7 and 3.0. The
data was recorded as an average of ten five-second acquisitions. Hydrodynamic radius
(Rh) of polymeric NPs were obtained using Dynamic software (version 7.0.3, Wyatt
Technology Corporation, Santa Barbara, CA) where the Stokes-Einstein equation is
applied to convert the intensity auto-correlation into the particle sizes.
Atomic Force Microscopy (AFM)
AFM images were taken using a Nanoscope III Bioscope (Digital Instrument,
Inc.) in tapping mode. 100 µl samples at pH 1.7 were drop-cast on freshly cleaved mica
surfaces, allowed to sit for several minutes, and then gently washed with DI water, and
air-dried. AFM cantilevers were purchased from TED Pella Inc., CA (BS-Tap 300AL-G50). The tip has radius of curvature <10 nm, length 125 µm, width 30 µm, and thickness
4 µm employed with a 40 N/m force constant. Images were collected at different size
scales, scan angles, and scan rate from 1 to 2 Hz.
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Fourier Transformed Infrared Spectroscopy (FTIR)
Both nPM (0.4 M) and 3F (0.4 M) solutions were prepared at pH 1.7, as described
before. FTIR readings were taken using a Varian 660-IR platform with a horizontal single
reflection Pike Technologies MIRacle attenuated total reflectance (ATR) unit, fitted with
a ZnSe crystal. 100 µl samples of nPM or 3F were dropped on the platform for taking the
readings. A method was constructed and used with Resolution Pro Version 5.1.0.822 for
both nPM and 3F samples. Spectra were taken after averaging 20 scans over the range of
600 to 2000 cm-1, with a resolution of 1 cm-1. Prior to each reading, a blank background
was acquired with the appropriate samples.
Zeta potential
Zeta potential was measured with a ZetaPlus zeta meter (Brookhaven Instruments
Corporation, Holtsville, NY). 100 µl aliquots of 3F or nPM solutions at defined reaction
times were added to 1 ml KCl (1 mM) in the instrument cuvette. The KCl solution was
prepared at pH 1.7 and 3.0 to match the pH of the nPM and 3F solutions.

2.4 Result and Discussion
Visual observation of the hydrolysis and condensation kinetic process can give a
clear idea of how and when each of the steps occur at different pH for both nPM and 3F.
Figure 2-2 shows the images of the hydrolysis and condensation process of (a) nPM and
(b) 3F at four different pH 1.7, 2.0, 2.5, and 3.0 over time. Since the density of nPM
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(0.932 g/mL) is lower than the water, prior to hydrolysis nPM floats on the top of the
water as a concave shaped lens in all the reaction tubes, irrespective of the investigated
pH.

Figure 2-2. Visual observation of the hydrolysis and condensation kinetics of (a) nPM
(0.4 M) and (b) 3F (0.4 M) as influenced by pH. The solution pH values are 1.7, 2.0, 2.5,
and 3.0 from left to right for the tubes in each image, with the images taken at the
indicated times following initiation of the reaction. The red lines highlight the boundary
of the unhydrolyzed nPM or 3F with the solutions; in the last panels the red lines indicate
condensation products that have settled out of solution.
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As seen in Figure 2-2, after 120±10 min at pH 1.7, the nPM reaction tube solution
is turbid, indicating condensation product formation. At higher pH values, hydrolysis is
not yet complete, but it has progressed significantly by 120 min, which can be observed
as depletion of the nPM layers at the top of the solutions. After 180±20 min, the nPM
reaction at pH 2.0 was in a condensation state, while at pH 2.5 the nPM lens had
disappeared, but the bulk solution was not yet turbid, indicating a hydrolyzed state. At
this same time, the pH 3.0 solution was still in a partially hydrolyzed state. After
1440±200 min at pH 1.7, 2.0, and 2.5, condensed particles have settled at the bottom of
the reaction tubes; whereas condensation has barely started for nPM at pH 3.0.
A similar pH-dependent pattern of hydrolysis and condensation can be observed
for 3F (Figure 2-2 (b)). However, in contrast to the nPM, the 3F hydrolysis and
condensation reactions are slower than the corresponding pH values for nPM. 3F is
denser than water and formed a convex lens on the bottom of the reaction tube. After
300±50 min, condensation started in the pH 1.7 reaction tube. At higher pH values
condensation was not observed, but the volumes of the 3F lenses decreased due to
ongoing hydrolysis. After 480±40 min, the reaction at pH 2.0 began to form condensation
products, whereas reactions at pH 2.5 and 3.0 were still in the hydrolysis state. After
1080±60 min, the reaction tube at pH 3.0 turned into a condensation state, and at other
pH values, condensed polymeric particles started to settle, forming what appeared to be a
gel at the bottom of the reaction tubes.
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A more quantitative assessment of the hydrolysis and condensation process was
attained using Turbiscan to measure the transmissivity of light through the reaction
solutions at defined heights (e.g. at the top of the tube for nPM, and the bottom for 3F).
Figure 2-3 shows the turbidity-based hydrolysis kinetics of nPM obtained by Turbiscan.
These data were taken from the very top of the solution in the tube where unhydrolyzed
nPM, which is less dense than water, was suspended as a lens. These Turbiscan-analyzed
data clearly showed the hydrolyzed and condensation periods at pH 1.7, 2.0, 3.0, and 4.0.
At pH 1.7, the transmissivity was 100 % after 40±5 min, compared to 0 % at the
beginning, which means that all the nPM was hydrolyzed at this time. This transmissivity
immediately started to reduce, reaching 2±0.5 % after 80±5 min.

Figure 2-3. Hydrolysis and condensation kinetics of nPM based on transmissivity, using
Turbiscan-analyzed data at pH 1.7, 2.0, 3.0, and 4.0.
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Transmissivity started to increase by as much as 50±5 % after 900±50 min, as
some of the condensed particles possibly started to drop from the solution. Similarly, for
pH 2.0, transmissivity was 2±0.5 % at the beginning, and it increased as the hydrolysis
was initiated, reaching 90±5 % after 105±5 min; and it remained at this value for 10±1
min, indicating that the hydrolysis products remained stable. Initiating of condensation
was indicated as the transmissivity dropped, and reached 1 % after 160±10 min, after
which it started to increase again, likely indicating that some particles started to separate
from the solution and reached 50±4 % after 850±40 min. At pH 3.0, transmissivity
increased from 0 % to 90±2 % after 240±20 min, as hydrolysis reached completion. This
optimum, fully hydrolyzed state remained stable for 460±30 min, at which time
condensation started. Within 180±20 min, turbidity became highest, as transmissivity
turned to 7±1 % after 885±100 min. After this, transmissivity started to increase and
turned to 40 % at 2700±100 min, as particles started to separate and settle at the bottom.
At pH 4.0, transmissivity increased from 0 % to 90±2 % in 440±40 min, and this
hydrolyzed state remained stable for 1650±50 min, before condensation started, as
indicated by a reduction in transmissivity. The transmissivity reached a minimum of
12±2 % after 2750±200 min, after which it started to increase again; and decrease of
transmissivity fluctuated as hydrolysis and condensation continued.
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Figure 2-4 shows the 3F Turbiscan hydrolysis and condensation data at pH 1.7,
2.0, 3.0, and 4.0. For 3F transmitted light was measured at the bottom of the tube, where
the dense unhydrolyzed 3F formed a lens. Transmissivity was 5±1 % at the beginning,
but after 30±5 min it increased to 65±5 %, as the lens decreased in size via solubilization
of hydrolyzed 3F. A fully hydrolyzed state was not attained at pH 1.7 for 3F, as indicated
by the subsequent reduction in transmissivity. Unlike in the case of nPM, maximum
transmissivity was never more than 65±5 % for 3F at pH 1.7, indicating that under these
conditions 3F was unable to be fully hydrolyzed by the time condensation began. The
transmissivity continued to decrease for 120±8 min, reaching 30±3 %, after which it
increased again and plateaued at 60±5 % after 225 min, due to scattering from the NPs.

2
.

Figure 2-4. Hydrolysis and condensation kinetics of 3F, based on transmissivity, using
Turbiscan-analyzed data at pH 1.7, 2.0, 3.0, and 4.0.
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As seen in Figure 2-4, at pH 2.0, the 3F hydrolysis and condensation kinetics
followed a similar trend as 3F at pH 1.7, with the noted difference of a slower initial
hydrolysis rate at the slightly higher pH.
At pH 3.0, the hydrolysis rate further slowed, requiring 195±15 min to reach a
transmissivity of 87±5 % that was stable for 585±50 min. This plateau represents a period
of stable hydrolysis product. Condensation reduced the transmissivity to 65±3 % after
750±75 min. A similar trend of decreasing hydrolysis rate was observed as pH 4.0, as the
transmissivity increased to 82±5 % after 270±35 min and remained stable until 510±90
min. The Turbiscan measurements clearly reveal optimal windows in which the two
silanes are hydrolyzed, but condensation does not appear to be occurring.
To better assess the start of condensation, a more sensitive technique was
employed. DLS was used to understand the evolution of the polymeric particles during
the condensation process at acidic pH. Figure 2-5 shows a comparative hydrodynamic
radius (Rh) of the polymeric NPs formed during the hydrolysis and condensation of 3F
and nPM at pH 1.7. For nPM, after 80±10 min of hydrolysis, NPs started to form as
condensation started. Typically, particles are called “nano” when sizes are below 100 nm
in at least one dimension. However, referring to particles as “nano” widely varies
depending on their application fields, and the size range often goes above 100 nm and up
to 500 nm.
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Figure 2-5. DLS comparison of evolution of polymeric NPs formation during the
hydrolysis and condensation process of nPM and 3F at pH 1.7.
After 175±25 min, once the Rh became more than 1150±100 nm, they started to
either separate from the solution or become larger than 2 µm in size, which is beyond the
limit of detection for the DLS instrument. A aimilar pattern was observed in the case of
3F, as NPs started to form only after 160±20 min, where hydrolysis ended and
condensation started. After 375±30 min, Rh was 1255±100 nm, and after that, no more
particles could be observed, as particles either precipitated from the solution or became
too large to be measured by DLS. As condensation progressed, NPs started to evolve with
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three distinct slopes of K1 (30.7), K2 (19.2), and K3 (7.8) for nPM and K1’ (3.2), K2’
(13.2), and K3’ (5.0) for 3F, as shown in the condensation profiles (Figure 2-5). The
slower hydrolysis and condensation kinetics of 3F compared to nPM could be due to the
presence of the hydrophobic tri-fluoro group in 3F, which hinders the hydrolysis and
condensation steps shown in Figure 2-1. The three distinct slopes shown in the
condensation profiles of both 3F and nPM could represent the condensation steps such as
(021), (012), and (003) shown in Figure 2-1.
At pH 3.0, evolution of the polymeric particles was distinct, as compared to pH
1.7. At pH 3.0, polymeric particles started to appear earlier in the 3F solution, compared
to the nPM solution (Figure 2-6). Polymeric particles started to appear at 1400±150 min
in the 3F solution, which kept growing until 3400±250 min; then particles became either
too big to be measured by DLS or precipitated from the solution out of the light path. In
the nPM solution, particles started to appear at 2100±150 min and kept growing until
3100±200 min, and then no particles could be detected. But after 3700±300 min, particles
could be measured again until 4500±150 min; then particles disappeared and reappeared
again at 4800±200 min. This appearance and disappearance of particles could be due to
the continuous separation of larger particles form the solution and remodeling of the
particles. The system was unstirred and the temperature held constant. At pH 3.0,
condensation progressed with four distinct slopes of K1’’ (0.4), K2’’ (1.8), K3’’ (-0.6),
and K4’’ (0.7) in the 3F profile, but only one (K1’’’ = 1.4) in the nPM.
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Figure 2-6. DLS comparison of evolution of polymeric NPs formation during the
hydrolysis and condensation process of nPM and 3F at pH 3.0.
Correlations of transmissivities observed by Turbiscan with the hydrodynamic
radiuses (Rh) of the polymeric particles measured by DLS at pH 1.7 and 3.0 for both nPM
and 3F are shown in Figures 2-7 to 2-10. To compare the Turbiscan data with DLS data,
transmissivity of the solution at the middle of the tube was compared, to measure
turbidity arising from condensation rather than transmissivity changes due to depletion of
the starting silanes that formed lenses. During the DLS analysis, 0.1 M nPM and 3F were
used for the hydrolysis and condensation reaction unlike the concentration used for the
Turbiscan study, where 0.4 M nPM and 3F were used. The use of low concentration was
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necessary because DLS is unable to measure higher concentrations during the hydrolysis
and condensation process for both nPM and 3F, due to the cuvette geometry.

Figure 2-7. Correlation of Turbiscan transmission data with the DLS polymeric size
(hydrodynamic radius, Rh) for nPM hydrolysis and condensation kinetics at pH 1.7.
Figure 2-7 shows the comparative data of Turbiscan and DLS of nPM at pH 1.7.
Even though Turbiscan data show that the transmissivity started to decrease after 60±5
min due to the turbidity in the solution, polymeric particles appeared only after 90±10
min in DLS. Two factors could be behind this delay of size appearance in DLS: first, it
could be due to the use of lower concentration of nPM; and second, it could be due to the
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fact that at the beginning of the particles’ formation, their sizes were too small to be
observed by DLS. Once transmissivity turned 0 %, it started to increase again, as it
appeared in case of transmissivity at the top.
The Turbiscan and DLS data for 3F at pH 1.7 (Figure 2-8) follow the same
general trend as for nPM (Figure 2-7). In this case, polymeric NPs observed by DLS
appeared earlier than the turbidity increase observed by Turbiscan. Polymeric particles
started to appear in the DLS profile after 180±20 min, but were not of sufficient size or
concentration to reduce light transmission in the Turbiscan, which began to decrease after
240±30 min. The reason could be the height difference of the data point of where the
reading was taken. After almost the same time (250±30 min), when the particles started
to separate or become too large to be detected by DLS, the Turbiscan reading could be
observed having the lowest transmissivity.
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Figure 2-8. Correlation of Turbiscan-analyzed transmission data with the DLS-obtained
polymeric size (hydrodynamic radius, Rh) for 3F hydrolysis and condensation kinetics at
pH 1.7.
Figure 2-9 shows the comparative data for nPM at pH 3.0, where light
transmissivity started to reduce far earlier (700±80 min) than the time where polymeric
particles started to appear in DLS (2100±100 min). This major time difference could be
due to the difference in surface to volume ratio in the liquid-air and liquid-liquid interface
ratio in the two solution containers used for Turbiscan and DLS. Also, the height
difference of the sampling points in the tubes could be a factor as well. After 1000±60
min, the Turbiscan data showed the lowest transmissivity, and then a sudden increase was
observed at 1060±60 min, which could be due to the aggregation / sedimentation of
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larger particle formations from the solution. This pattern can be observed in the DLS
data, but only after 3320±150 min.

Figure 2-9. Correlation of Turbiscan transmission data with the DLS-obtained particle
sizes (hydrodynamic radius, Rh) for nPM during the hydrolysis and condensation kinetics
at pH 3.0.
A similar trend could be seen in case of 3F at pH 3.0 (Figure 2-10), where the
Turbiscan-analyzed data showed that the transmissivity started to reduce after 840±60
min, but these polymeric particles could be seen in DLS only after 1420±100 min.
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Figure 2-10. Correlation of Turbiscan-analyzed transmission data with the DLS-obtained
particle sizes (hydrodynamic radius, Rh) during 3F hydrolysis and condensation kinetics
at pH 3.0.
Similar to the nPM at pH 3.0, the reduction and increase of transmissivity and
hydrodynamic sizes were observed as condensation continued for 3F at pH 3.0
Figure 2-11 (a) and (b) show the AFM images of the polymeric NPs formed
during the condensation process of nPM at pH 1.7. Polymeric NPs became 10±5 to
100±20 nm after 180 min (Figure 2-11 (a)), but over the time, these particles became
irregular in shapes and sizes. Figure 2-11 (b) shows the transformation of the polymeric
NPs after 1440 min, where large and irregular particles can be observed.
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Figure 2-11. AFM images of polymeric NPs formed following the condensation of nPM
after (a) 180 min and (b) 1440 min.
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Similarly, Figure 2-12 (a) and (b) show the AFM images of the polymeric NPs formed

! !

during the condensation of 3F at pH 1.7. Polymeric NPs became 12±5 to 200±30 nm
after 300 min (Figure 2-12 (a)). These particles kept growing over time, and after 1440
min, micron-sized particles were observed, along with the nano-sized particles (Figure 212 (b)).

55

a)

!100!nm!

!0!nm!

!500

!0

nm

b)

nm

!1µm

!1!μm!

Figure 2-12. AFM images of polymeric NPs formed following the condensation of nPM
after (a) 300 min and (b) 1440 min.
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The ATR-FTIR spectra of nPM (0.4 M) and 3F (0.4 M) were taken at various

!

!

time intervals during the hydrolysis and condensation at pH 1.7. Figures 2-13 and 2-14
show the ATR-FTIR spectra of the nPM and 3F solutions, respectively, at different
transition phases during hydrolysis and condensation. Since spectra were taken directly
from the aqueous solutions, the H-O-H bending peak can be observed in all the spectra of
nPM (at 1635 cm-1) or 3F (at 1650 cm-1) throughout the hydrolysis and condensation
processes.
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Figure 2-13. ATR-FTIR spectra of nPM at defined times during the hydrolysis and
condensation process.
A Si-OH band appeared after 0.5 h at 900 cm-1 in the ATR-FTIR spectrum of the
nPM (Figure 2-13), indicating ongoing hydrolysis. At this time another peak representing
a Si-CH2 band was also observed at 1015 cm-1. After 1.5 h, as condensation began, this
Si-OH band disappeared and the stretching vibration of Si-O-Si started to appear at 10001100 cm-1 (Figure 2-13). At this time (1.5 h), a strong Si-alkoxy (Si-O-CH3) band was
also observed at 1190 cm-1, which implies that at this time hydrolysis was still in

57
progress, even though condensation has started already. After 2 h, this peak for the Si-OCH3 band disappeared, confirming the end of the hydrolysis. As condensation continued,
the bands representing Si-O-Si, started to disappear (3.5 h and 12 h) as polymeric
particles got larger and precipitated from the solution to form a gel at the bottom. After
12 h, the peaks for the Si-O-Si and Si-O-CH3 bands appeared in the spectrum
representing the gel from the bottom. Strong Si-CH2 band at 1215 cm-1 and some
vibrational peaks for C-H and C-H2 can also be observed at 1315 to 1455 cm-1.
Unlike the nPM spectra, 3F spectra did not show a strong band for Si-OH at 900
cm-1 during the possible hydrolysis period of 3F (Figure 2-14), but a weak Si-OH band
appeared at 935 cm-1 in the spectra representing the solution at 2.5 h, 3.5 h, and 6 h, but
not at 24 h. After 2.5 h, stretching vibration of Si-O-Si appeared at 1000-1100 cm-1,
confirming condensation. Strong stretching vibration for –CF was observed in all the
spectra at 1215 and 1267 cm-1. Absorbance intensity at 1215 cm-1 was stronger, due to the
combination of Si-CH2 and –CF bands. All the peaks representing the Si-O-Si band in
between 1000 cm-1 to 1100 cm-1 appeared in the spectrum representing the gel at the
bottom after 24 h. Vibrations of C-H and C-H2 also were observed in a wide range of
wavenumbers (1315 cm-1 to 1450 cm-1) in this spectrum.
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Figure 2-14. ATR-FTIR spectra of 3F at defined times during the hydrolysis and
condensation process.
Zeta potential was studied to understand the physical phenomena such as surface
charges of the condensed particles or aggregates. Zeta potential measures the average
surface charge of the particles in a colloidal suspension with millivolt resolution. Figure
2-15 shows the zeta potential of the particles formed during the hydrolysis and
condensation of nPM at pH 1.7 and 3.0. At pH 1.7, the zeta potential of condensed
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polymeric particles fluctuated in between 0 to -5 mV. Since the isoelectric point of silica
particles is close to pH 2.0, zeta potential of the polymeric particles generated from nPM
at pH 1.7 were also expected to be close to zero.

Figure 2-15. Zeta potential of polymeric NPs evolving from nPM during the hydrolysis
and condensation processes at pH 1.7 and 3.0.
At pH 3.0, the nPM NPs have a zeta potential between -7 mV and -9 mV. The
increase in negative charge compared to the particles formed at pH 1.7 is expected if free
silanol groups are present on the nPM NPs that would be deprotonated as the pH is
increased above the isoelectric point.
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Figure 2-16. Zeta potential of polymeric NPs evolve from 3F during the hydrolysis and
condensation process at pH 1.7 and 3.0.
Figure 2-16 shows the zeta potential of the particles formed during the hydrolysis
and condensation of 3F at pH 1.7 and 3.0. At pH 1.7, zeta potential of the fluorinated
polymeric particles was near zero mV until 2300 min, but it decreased to -8 mV after
2800 min. These decreases in the zeta potential value could be due to the continual
growth of polymeric particles with higher surface charges. At pH 3.0, the zeta potential
values remained close to zero mV, similar to pH 1.7 until 2300 min, but they surprisingly
increased to 17 mV after 2800 min.
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2.5 Conclusion
These studies on the evolution of polymeric NPs during hydrolysis and
condensation of two types of hydrophobic tri-alkoxysilanes showed the distinct pattern of
hydrolysis and condensation rates at various pH. These patterns were correlated using the
complementary methods of turbidity scanning with Turbiscan, and monitoring evolution
of particles with DLS. Hydrolysis and condensation kinetic profiles of 3F and nPM
allowed the processes of hydrolysis and condensation to be tuned through the selection of
pH, to provide optimal interaction with biological molecules for various applications,
ranging from enzyme encapsulation to the modulation of protein conformation. AFM
images confirmed the NP sizes, and revealed heterogeneity in shapes, while ATR-FTIR
spectra showed the chemical compositions of the polymeric NPs generated during the
condensation. Of particular interest was the presence of a silanol signal in the NP spectra,
suggesting that condensation did not consume all silanols. Zeta potential confirmed this
as it revealed a negative surface character on these nanoparticles. Surface available
silanols combined with the hydrophobic tri-fluoro or methyl groups are desirable for
applications of these two hydrophobic silanes toward modulating the protein secondary
structures and corresponding fibrillation propensity.
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CHAPTER 3
SILANE-PROTEIN INTERACTIONS : FLUORINE-BASED SELF-ASSEMBLED
HYDROPHOBIC POLYMER NANOPARTICLES INHIBIT AMYLOID
FIBRILLATION OF ß-LACTOGLOBULIN

3.1 Abstract
Fluorinated polymeric nanoparticles (NPs) inhibited the amyloid fibrillation of blactoglobulin (BLG). Initially, inhibition of fibrillation was observed qualitatively by
DLS as hydrodynamic radius (Rh) in aqueous solution under the model conditions for
BLG to form fibrils. Later, AFM-analyzed morphological study confirmed the inhibition
of the amyloid fibrillation of BLG by the fluorinated polymeric NPs. Along with the
fluorinated polymeric NPs, fluorine-free or methylated polymeric NPs were also tested
against the amyloid fibrillation, and AFM images showed that they partially inhibited the
fibrillation. During the fibril inhibition process, protein-fluorinated silica-based stable
nanocomposite particles with the sizes <12 nm were generated. Deconvoluted ATR-FTIR
spectra showed that β-sheet decreased by 29 % and 11% after BLG was treated with
fluorinated polymeric NPs and methylated polymeric NPs, respectively. Docking study
showed the existence of hydrogen bonding between BLG and both fluorinated and
methylated silanol monomers.
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3.2 Introduction
Accumulation of fibrillated protein aggregates in the brain or other tissues are
commonly known as amyloid. Amyloid is a pathological feature of a series of
neurodegenerative disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD),
Huntington’s disease (HD), type II diabetes, and Prion disease. (1-8) Amyloid forms due
to the destabilization of a-helices and the simultaneous formation of highly ordered cross
β-sheet structures that assemble into the characteristic plaques. (9-11) Also, the presence
of buried hydrophobic surfaces or favorable packing of side chains contribute to the
stability of the amyloid structure and makes it very resistant to degradation and
depolymerization. The amyloid hypothesis correlates disease symptoms and sequence
with fibrils and plaques, thus plaque-targeting is widely investigated. Molecules that
stabilize a-helix or inhibit the formation of b-sheets are potential candidates to maintain
the native structure of the protein and avoid amyloid formation. Thus, molecules capable
of inducing conformational transition in protein should be used to develop the
therapeutics to stabilize the nonpathogenic conformation. Also, the therapeutics should be
able to prevent the recruitment of native proteins by the misfolded / pathogenic seed,
which eventually will inhibit the amyloid formation. At present, however, there is no
effective drug to cure the amyloid-based diseases, and the treatment of symptoms is also
extremely limited. Most of the drugs that have been developed to target amyloid-based
diseases have failed at various stages of their clinical trials. (12)
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Several types of molecules have shown inhibiting ability against the amyloid
growth, such as various biomolecules including peptides / antibodies, drugs, small
molecules including phenolic compounds, gene therapy, and chaperones. (13-30) With
the recent advancement of nanotechnology, a new therapeutic avenue has opened with
the use of various NPs against amyloid fibrillation of amyloidogenic proteins. The
potential influence of NPs on protein fibrillation is the function of their surface chemical
functional groups, their interfacial properties including surface charges, and their shapes
and sizes, which decide the surface to the volume ratio. Studies have shown that NPs are
capable of crossing the blood-brain barrier (BBB) and have greater in vivo stability. (17)
NPs can both inhibit and promote amyloid fibrillation, depending on surface properties,
core material, assembly, concentration, and type of functional molecules present on it.
For example, copolymer particles of N-isopropylacrylamide: N-tert-butylacrylamide,
cerium oxide, quantum dots (QDs), carbon nanotubes, citrate-capped gold NPs, and
titanium oxide are reported to promote protein assembly into amyloid fibrils in vitro, by
assisting the nucleation process. (31-45), In contrast, various inorganic NPs, hydrophobic
NPs, NPs functionalized with hydrophobic molecules and specific affinity molecules
such as curcumin (46-48), dextran (49), and sialic acid (50-51) reportedly inhibit
fibrillation processes.
Among the functionalized NPs, fluorinated NPs are of special interest due to the
properties of fluorine atoms: addition of fluorine atoms increases the pharmacological
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activity. Thus, various fluorinated antibiotics, anticancer, anti-inflammatory, and antiviral
therapeutics have been reported. (52-54) Another beneficial property of the fluorine
substitution is the increase of BBB permeability achieved by the modification of the
lipophilicity or amine pKa. In fact, approximately a quarter of all the drugs developed for
pharmaceutical purposes have the presence of fluorine atoms. (55-58) Fluoro-substituted
alcohols such as TFE (2,2,2-trifluoroethanol) and HFIP (1,1,1,3,3,3-hexafluoro-2propanol) are strong inducers of protein and peptide structures. (59) The hydroxyl group
in HFIP and TFE preferentially binds with a carbonyl oxygen of protein backbone and
acts as a protein donor, whereas the strong electronegative F group acts as a hydrogen
acceptor, forming H-bonds with proton donor groups on protein. (58-61) As a
consequence, the solvent exposure of the amide is minimized and the intra-polypeptide
hydrogen bonding of the amide group is favored, leading to increased helical
propensities. Increased hydrophobicity, which arises from both hydrocarbon groups and
multiple F atoms in the fluoro-alcohols, plays an essential role in denaturing protein
secondary structures and inducing the formation of helical structures. (58) A major issue
with these fluoro-substituted alcohols as amyloid fibril inhibitors is their application as
therapeutic agent to the targeted proteins. Thus, fluorinated polymeric NPs having
multiple stable hydroxyl groups with hydrophobic characteristics are desirable to be used
as therapeutic agents to inhibit amyloid fibrillation, which can be achieved using a
polymerizable analog of fluoro-alcohol such as hydrolyzed fluoro-silane.
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Our recent works suggest that fluoro-silane 3,3,3-trifluoropropyl trimethoxy
silane (3F) is very highly efficient as protein secondary structure inducer in its
hydrolyzed states. (62) Hydrolyzed 3F (H3F) can convert β-sheet structure to α-helix,
where 3F- groups promote 3F-protein interaction by forming H-bonds with hydrogen
donors on the protein; consequently disrupting the intra-molecular H-bonds between
distant residues involved in β-sheets, and favoring H-bonding between more proximal
amino acids on the polypeptide chain, leading to α-helices. Given that the β-sheet
structure is the reason why amyloid fibrils formed, fluorinated polymeric NPs having the
same characteristics as H3F capable of inducing β-sheet would be a strong candidate as
amyloid inhibitor, which could be achieved by condensing the H3F.
In this study, anti-fibrillar activity of fluorinated polymeric NPs was investigated
against a model template protein β-lactoglobulin (BLG) which exhibits predominantly βsheet secondary structure. BLG is a globular protein containing 162 amino acids, with a
MW of 18.4K g/mol, IEP of 5.1, and an internal hydrophobic core surrounded by a
hydrophilic exterior. In order for BLG to form amyloid fibrils, it first refolded into
protofilament at acidic pH and at temperature >80°C, where the protein possesses a
dominant positive charge. (63) If heating continues for a few hours, the contour length of
these protofilaments become > 0.5 µm, forming amyloid fibrils. (64) Since the fibrils of
globular proteins have a similar structure to those causing amyloidosis diseases, BLG has
been widely investigated to understand the amyloid fibril formation. (65-77)
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BLG is not only well characterized, it is also easily available and relatively cheap,
and that is the reason why we have selected it as our model template protein. Nonfluorinated or methylated polymeric NPs were also investigated against BLG, to
demonstrate the importance of the fluorine moieties in the NPs for anti-fibrillation
activities; and these methylated polymeric NPs were obtained with the condensation of
hydrolyzed n-propyltrimethoxy silane (HnPM).
The objective of this study was to investigate the modulation of fibril properties
of BLG using fluorinated and methylated polymeric NPs, study the secondary structural
transformation in the BLG during the BLG-NPs interaction, and molecular docking of
protein-ligand interactions.

3.3 Materials
3,3,3-trifluoropropyl trimethoxy silane (3F, > 95 % purity, MW = 218.3, d = 1.14
g/ml) and n-propyltrimethoxy silane (nPM, > 95 % purity, MW = 164.3, d = 0.94 g/ml)
were purchased from Gelest, Inc. (Morrisville, PA). β-lactoglobulin from bovine milk
(BLG, > 90 % purity, MW = 18,400) was obtained from Sigma-Aldrich (St. Louis, MO);
the thioflavin T powder was purchased from EMD Millipore, Darmstadt, Germany; and
Muscovite mica was purchased from SPI supplies for the AFM study (PA, USA).
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3.4 Experimental methods
Preparation of BLG solutions
BLG stock solution was prepared by dissolving 200 mg of BLG powder in 10 ml
double distilled deionized (DI) water at pH 2.0 with gentle shaking, which gave 20 mg/ml
(1.088 mM) solution. The dissolved BLG solution was then filtered through a 0.2 µm
syringe filter (Millex-GS, Millipore) and stored at 4°C.
Dynamic Light Scattering (DLS) analysis
Evolution of the hydrodynamic sizes (Rh) of the polymeric NPs during the
hydrolysis and condensation of nPM and 3F was analyzed using DLS (DynaPro
NanoStar, Wyatt Technology Corporation, Santa Barbara, CA). Measurements were
taken using a quartz cuvette (JC-426, 1 µl) filled with 0.7 ml 3F (0.1 M) or nPM (0.1 M)
aqueous solutions at pH 2.0. Hydrolysis and condensation kinetics of 3F and nPM were
collected over 10 h. For the BLG fibrillation study, initially 0.7 ml BLG solution (1
mg/ml (0.013 mM) and pH 2.0) was added in the cuvette, and its Rh was measured. After
that, the same BLG solution was heated for 3 h at 90°C, to observe the Rh of the fibrils.
To measure the Rh sizes of the products generated after the interaction of BLG with
fluorinated and methylated polymeric NPs, 0.7 ml of 3F or nPM solutions (0.2 M) at pH
2.0 were monitored as the hydrolysis progressed. After the hydrolysis was completed, the
0.35 ml solution was replaced with 0.35 ml of 2 mg/ml (0.026 mM) BLG solution (at pH
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2.0) and the Rh size was measured after heating the sample for 3 h at 90°C. For the
control sample, 0.35 ml aqueous solution (at pH 2.0) was used without adding BLG.
Amyloid fibrillation with polymeric NPs
0.4 M 3F and nPM solutions were prepared adding 0.18 ml of 3F and nPM in 5
ml glass vials, where 2.32 ml of DI water (at pH 2.0) were already kept. As soon as all 3F
and nPM were hydrolyzed, condensation followed immediately, and started to form
polymeric NPs. Once all of the 3F and nPM were hydrolyzed, 0.75 ml 3F and nPM were
added separately to 0.25 ml of BLG (1.088 mM) solution in 5 ml glass vials with
magnetic stir bars in them. Reaction was let to occur for 5 min at room temperature
(23°C), then transferred to an oil bath with temperature of 90°C, and the samples were
heated for 5 h. For the control samples, in three separate glass vials, 3F (0.3 M), nPM
(0.3 M), and BLG (0.272 mM) were also heated at 90°C for 5 h. Reactions were stopped
using ice bath; and once solution temperature came down to room temperature, different
analyses were performed.
Thioflavin T (ThT) fluorescence assay
A stock solution of 3.0 mM ThT in phosphate-NaCl buffer (10 mM phosphate and
150 mM NaCl, pH 7.0) was filtered through a 0.2 µm syringe filter (Millex-GS,
Millipore). Stock solution was stored at 4°C in a brown glass bottle covered with
aluminum foil. Working solution was prepared by diluting stock solution 50-fold in
phosphate-NaCl buffer (the final ThT concentration was 60 µM). 200 µl samples were
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added on the 96-well plate from the 2.5 ml glass vials, where ThT and target solutions
were added at 3:1 ratio. Emission spectra were taken from 460 nm to 560 nm after
excitation at 440 nm, using a Synergy4 Hybrid Multi-Mode Micro Plate Reader (BioTek,
Inc., VT, USA).
Fibrillation analysis with Atomic Force Microscopy (AFM)
To observe the structural formation of BLG fibrils and polymeric NPs, AFM
images were taken using a Nanoscope III Bioscope (Digital Instrument, Inc.) in tapping
mode. 100 µl samples were dropped onto freshly cleaved mica surfaces, then gently
washed with DI water, and air-dried before taking AFM images. AFM tips were obtained
from TED Pella Inc., CA (TAP300AL-G-50).
Fourier Transformed Infrared Spectroscopy (FTIR)
The interactions of BLG with fluorinated and methylated polymeric NPs were
analyzed by FTIR using a Varian 660-IR with a horizontal single reflection Pike
Technologies MIRacle attenuated total reflectance (ATR) unit, fitted with a ZnSe crystal.
100µl samples were drop cast on the ZnSe crystal of the ATR platform and air-dried
before taking the reading. Readings were taken after averaging 20 scans over the range of
1200 cm-1 to 1800 cm-1, with a resolution of 1 cm-1. Prior to each reading, a background
scan was acquired. FTIR obtained spectra were later deconvoluted using ORIGIN PRO
2017, to ascertain the influence of the fluorinated and methylated polymeric NPs on the
secondary structural motifs of BLG, along with the untreated BLG and BLG fibrils.
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Docking studies
Docking study was performed using Autodock 4.2.6. The 3D structures of H3F
and HnPM monomers were drawn using Marvin software. BLG was interacted with H3F
and HnPM monomers using Autodock Tools 1.5.6. Hydrogen atoms were added and
Kollman charges were used to set the charges on BLG, and Gasteiger charges were added
to H3F and HnPM monomers. The docking grids were carried out with a default spacing
value of 1 Å, and grid volume 70×70×70 points, covering the entire surface of the BLG.
The protein molecule was set to rigid, while the ligand molecule was considered to be
flexible. In the docking simulation, a Lamarckian generic algorithm was used to generate
10 binding models, each of which was individually selected as the lowest binding energy
among a maximum of 2,700,000 evaluations. These 10 complexes were clustered
according to their root-mean-square deviation (RMSD) values and binding energies, in
order to distinguish the preferred binding model.
Statistical analysis
Triplicate samples were studied throughout the experiment, and average values
with the associated standard deviations were calculated and shown in the appropriate
Figures. One-way ANOVA test was performed using Sigma Plot 13.0.
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3.5 Results and Discussion
Hydrolysis was favored over condensation at acidic pH, and all three O-CH3 of 3F
and nPM underwent sequential hydrolysis, yielding silanols. Polymeric NPs containing
silanol were generated in aqueous media, as condensation followed the hydrolysis.
Presence of silanol in the NPs is desirable in the amyloid inhibition process, as it showed
the secondary structure inducing ability. (78) Aqueous synthesis of NPs makes them
suitable to be used in the biological system. The hydrolysis and condensation kinetic
profiles of 3F and nPM as well as the evolution of the hydrodynamic radius (Rh) of the
NPs are shown in Figure 3-1, obtained from DLS analyzed data. NPs started to appear as
the condensation began at 80±10 min for nPM and at 180±20 min for 3F. As
condensation progressed, NPs continued to grow and become >1 µm in 180±25 min for
nPM and in 400±50 min for 3F. The NPs” growth rate had a sudden jump after the Rh
size turned 400±20 nm for both 3F and nPM; and possibly the aggregation of the
individual NPs was due to electrostatic interactions.
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Figure 3-1. Evolution of hydrodynamic radius (Rh) sizes of 3F and nPM during the
hydrolysis and condensation process at pH 2.0. Arrows indicate the time when samples
were taken for the amyloid study.
Figure 3-2 shows the 3D structure and space-filling model of the NPs growth of
3F, which could start from 1 nm size and continue to grow. These polymeric NPs can
grow linearly or branchwise to form spherical particles, but still contain silanol
functionality, as shown by the 3D model structure of the NPs.
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Figure 3-2. Schematic of the 3D structure and space filling model for fluorinated
polymeric NPs, suggesting that both linear and cyclic geometries are possible, and silanol
as well as 3F moieties are present on the NP surface for interaction with proteins.
DLS has been widely used to determine the proteins and their fibril sizes in
solution. In this study, DLS was used to determine the hydrodynamic diameter of the
protein, fibrils, fluorinated and methylated polymeric NPs, and the composite particles
formed as the fibril inhibition process completed. Amyloid fibril inhibition study was
performed using NPs formed at the very early stage of the condensation of 3F and nPM,
shown as arrow in Figure 3-1, where NPs are in their smallest sizes. At this stage, along
with the newly formed polymeric 3F and nPM NPs, their free hydrolyzed 3F and nPM
monomers may also be available. These hydrolyzed monomers may also take part in the
amyloid inhibition process, as these monomers favor transition of beta-sheets into alpha-
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helices. The DLS study gives a comparative picture of the hydrodynamic sizes of the
products generated, observed after treating BLG with fluorinated and methylated
polymeric NPs.

Figure 3-3. Hydrodynamic diameter of BLG, fibrillated BLG, fluorinated and methylated
polymeric NPs treated BLG, and control fluorinated and methylated polymeric NPs. The
fibrillation of BLG was performed at 90°C for 5 h in DLS cuvette. Fluorinated and
methylated polymeric NPs were added in BLG (0.272 mM), and reacted for 5 min before
heating at 90°C for 5 h at pH 2.0.
Figure 3-3 shows the hydrodynamic diameter of BLG, potential BLG fibrils, and
evolved NPs during the amyloid inhibition process, using fluorinated and methylated
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polymeric NPs. The hydrodynamic diameter of BLG was observed as 4 nm at pH 2, and
after heating at 90°C for 5 h fibrils formed with a bimodal size distribution with peaks at
150 nm and 1µm. Bolisetty et al. conducted an experiment on the kinetic of the BLG
fibrillation, and observed similar bimodal fibril size distribution at 90°C. (79)
Hydrodynamic diameter of fluorinated and methylated polymeric NPs treated
BLG showed distinct size distribution compared to the control or untreated NPs. Bimodal
size distributions were observed for both the particles formed after 3F NPs treated with
BLG and untreated control NPs; but sizes reduced after 3F NPs (3±1 nm and 85±7 nm)
were treated with BLG, compared to the control NPs (19±2 nm and 110±10 nm).
Hydrodynamic diameter of nPM NPs treated BLG showed tri-modal size distribution
(7±1 nm, 60±3 nm and 500±40 nm), compared to the bimodal sized distribution (9±1 nm,
70±5 nm) of their control NPs. The reduction in the sizes observed after 3F NPs treated
BLG indicates the fibril inhibition, which was not observed in the case of nPM NPs
treated BLG. This reduction in size also indicates the possible termination of the NPs’
growth as they interact with BLG molecules. The appearance of the particles with the
size of 500±40 nm during the nPM NPs interaction with BLG indicates the possibility of
fibril formation.
Fluorescent dye such as ThT is widely used to determine the formation of
protein fibrils during the amyloid aggregation process. (80-90) When ThT reacted
with fibrillated protein, a specific binding between ThT and the β-sheet structure of fibrils
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formed, which enhanced the fluorescent intensity of ThT, indicating the presence of
fibrils. In this study, ThT fluorescence-based method was used to identify the fibrils in
the fluorinated and methylated polymeric NPs treated BLG solution. The spectrum
representing the BLG fibril-ThT in Figure 3-4 (a) and (b) shows that the fluorescence
intensity doubled, compared to the spectrum of nonfibrillated BLG-ThT, which confirms
the existence of fibrils.

Figure 3-4. Emission spectra of ThT fluorescence obtained from (a) fluorinated and (b)
methylated polymeric NPs treated BLG, along with fibrillated, nonfibrillated BLG, and
their controls.
Although the spectrum of nPM-ThT was observed identical to that of
nonfibrillated BLG-ThT, the intensity of the spectrum representing 3F-ThT increased.
The 3F NPs treated BLG-ThT emission spectrum was 70 times and nPM NPs treated
BLG-ThT was 3 times higher in fluorescence intensity, compared to that of nonfibrillated
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BLG-ThT. A comparative picture of the fluorescence intensity at 485 nm taken from all
the emission spectra of nonfibrillated BLG-ThT, fibrillated BLG-ThT, nPM-ThT, 3FThT and 3F and nPM NPs treated BLG-ThT is shown in Figure 3-5. Fluorescence
intensity was taken at 485 nm because intensities of all the spectra are observed as
optimum at this wavelength.

Figure 3-5. Comparison of ThT fluorescence intensity of fluorinated and methylated
polymeric NPs treated BLG along with fibrillated and nonfibrillated BLG (0.272 mM),
and their controls at 490 nm.
As fluorinated and methylated polymeric NPs are expected to inhibit the
fibrillation of BLG, increased fluorescence intensity could mean inefficiency in
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fibrillation inhibition. But a recently published report showed that ThT can bind with
silica gel and generate very high fluorescence. D'Amico et al. observed ThT entrapped in
the silica xerogel, resulting in high fluorescence intensity, compared to the free ThT
molecule. (91) The electrostatic interaction between positive ThT and negative ºSiO−
groups creates a very strong ThT+−SiO− bond, immobilizing ThT molecules inside the
pores of the xerogels. This electrostatic interaction strongly hinders the rotational
mobility of the ThT, increasing its overall fluorescence intensity. During the amyloid
inhibition process, fluorinated and methylated polymeric NPs went through the continual
condensation process, generating fluorinated and methylated silica colloids and BLGsilica composite colloids. These colloids contain a large number of ºSiO−, which
potentially could interact with positively charged ThT, resulting in enhanced fluorescence
intensity. Thus, lower fluorescence intensity of BLG fibrils, compared to 3F and nPM
treated BLG, could be due to the interaction between ThT and 3F-BLG / nPM-BLG
composites instead of BLG fibrils. Thus, success in inhibition of fibrillation by
fluorinated and methylated polymeric NPs is not distinguishable with these ThT
fluorescence spectra.
The fluorescence intensity of ThT after interacting with fluorinated and
methylated polymeric colloids shown in Figure 3-5 was much lower, relative to the
fluorescence intensity observed with 3F-BLG / nPM-BLG composites. This could be due
to the fact that the sample used from the 3F and nPM condensed solution might not have
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enough colloids in the sample interacted with ThT, since colloids tend to precipitate as
condensation continues. This also means that 3F-BLG / nPM-BLG composites tend to
remain suspended in solution for a longer time, compared to the fluorinated and
methylated polymeric NPs.
To have a comprehensive idea of the structures of protein fibrils, colloidal
particles and nanocomposites, nanoscopic image analysis was used. AFM is widely used
to observe the amyloid fibrils formation and analyze their structural properties. (65-68) In
this study, AFM images were taken to investigate the nanoscopic development in BLG
during the inhibition process by fluorinated and methylated polymeric NPs. Figure 3-6
shows the AFM images of untreated BLG, fluorinated and methylated polymeric NPs
treated BLG, along with the 3F and nPM associated NPs. Unheated BLG created a thin
layer of 2 nm on the mica surface (Figure 3-6 (a)) at pH 2.0; and after heated at 90°C for
5 h, BLG formed fibrils with various lengths and shapes (Figure 3-6 (b)). Figure 3-6 (c)
shows that two different NP-size groups were generated in the controlled system of 3F,
which were consistent with the DLS-obtained data described earlier. Fluorinated
polymeric NPs treated BLG showed no fibrils presence, but rather spherical NPs with
two distinct size groups of NPs, as shown in Figure 3-6 (d).
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Figure 3-6. AFM images of (a) BLG (0.272 mM), (b) fibrillated BLG (0.272 mM), (c)
evolved particles after heating fluorinated polymeric NPs, (d) particles formed after
fluorinated polymeric NPs reacted with BLG (0.272 mM) for 5 min and then heated, (e)
evolved particles after heating methylated polymeric NPs, and (f) particles formed after
methylated polymeric NPs reacted with BLG (0.272 mM) for 5 min and then heated.
These results confirm the amyloid inhibition by fluorinated polymeric NPs and
associated NPs generated during the inhibition process. The NPs generated during the
amyloid inhibition process are relatively monodispersed compared to the NPs generated
due to condensation of fluorinated polymeric NPs alone. These monodispersed NPs could
be the composite material consisting of both 3F and BLG or only 3F.
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Unlike fluorinated polymeric NPs treated BLG, fibrils were generated when BLG
was treated with methylated polymeric NPs. However, these fibrils were thinner,
relatively longer in size, and fewer in number, compared to the untreated BLG fibrils
shown in Figure 3-6 (e) and (f). Along with fibrils, relatively small sized NPs were also
observed, which could be composite materials consisting of nPM and BLG or simply NPs
generated from the condensation of nPM.
To analyze the length, size, and number of the BLG fibrils, composite NPs of 3F
and nPM with BLG and their non-composite NPs were generated during the amyloid
fibril inhibition process, and a series of histograms were plotted based on the AFM
images shown in Figure 3-7.

Figure 3-7. Histograms of the sizes of the (a) BLG fibrils formed at 90°C for 5 h, and
(b) BLG fibrils formed after methylated polymeric NPs reacted with BLG (0.272 mM) and
then heated.
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The histogram of BLG fibrils showed that around 50±5 fibrils were <0.5 µm in
length, and the majority of the fibrils were larger than 2 µm but smaller than 5 µm
(Figure 3-7 (a)). No fibril was formed when BLG was treated with fluorinated polymeric
NPs, but when treated with methylated polymeric NPs, fibrils were formed. These fibrils
were fewer in number, compared to the untreated BLG fibrils (Figure (3-7 (b)).
The histogram of nPM treated BLG also showed that few fibrils were below 0.5
µm, but the overall size of the fibril length increased, compared to the untreated BLG
fibrils; and the longest fibril was measured as >12 µm.

Figure 3-8. Histograms of the sizes of the (a) evolved particles after heating fluorinated
polymeric NPs at 90°C for 5 h, and (b) particles formed after fluorinated polymeric NPs
reacted with BLG (0.272 mM) for 5 min and were then heated at 90°C for 5 h. The insert
in the Figures shows the amplified frequency of the indicated particle size zones.
The histograms of the NPs generated from the fluorinated and methylated
polymeric NPs used in the fibrillation inhibition process are shown along with the NPs
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generated from the control 3F and nPM NPs in Figures 3-8 and 3-9. Figure 3-8 (a) shows
that NPs generated from fluorinated polymeric NPs after heating for 5 h at 90°C were
mostly below 5±1 nm in diameter, and some ranged from 30±2 nm to 60±2 nm, which
were obtained from the height profile from the AFM images. But as 3F NPs were used in
the inhibition process against BLG, NPs sizes decreased, as shown in Figure 3-8 (b),
where the majority of NPs ranges below 4 nm and in the range between 10±2 to 40±5
nm, with a bimodal distribution.

Figure 3-9. Histograms of the sizes of the (a) evolved particles after heating methylated
polymeric NPs at 90°C for 5 h, (b) particles formed after methylated polymeric NPs
reacted with BLG (0.272 mM) for 5 min, and then heated at 90°C for 5 h.
This decrease in size indicates that the BLG interacting 3F NPs were restricted in
growth. Similar to the fluorinated polymeric NPs, the histogram of the particles generated
from the methylated polymeric NPs used to inhibit the BLG fibrillation showed decrease

88
in sizes and number, compared to the NPs generated from control nPM, shown in Figure
3-9 (a) and (b). Although methylated polymeric NPs did not inhibit the fibril growth of
BLG, this histogram showed that it interacted with BLG, which hindered the further
growth of the methylated polymeric NPs.
As the AFM images show, the fibrils and NPs generated from fluorinated and
methylated polymeric NPs after the inhibition process were distinct in size, shape, and
length, compared to the untreated BLG fibrils, fluorinated and methylated polymeric
NPs; and a cross-sectional analysis gives further understanding of their structural
formation, as shown in Figure 3-10.
The height profiles obtained from the cross-section of the AFM images of BLG
fibrils are shown in Figure 3-10 (a) and fluorinated and methylated polymeric NPs treated
BLG and associated NPs are shown in Figure 3-10 (b) and (c), respectively. The height of
the BLG fibrils ranged from 2±0.5 nm to 12±1 nm, where the majority were between
4±0.5 nm to 6±1nm, and these numbers were consistent with published reports. (65)
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Figure 3-10. Height profile of (a) BLG fibrils (0.272 mM), (b) 3F-BLG composite NPs
formed after fluorinated polymeric NPs reacted with BLG (0.272 mM) for 5 min and then
were heated, and (c) BLG fibrils and nPM-BLG composite NPs formed after methylated
polymeric NPs reacted with BLG (0.272 mM) for 5 min and then were heated.
The height of the NPs generated after the fluorinated polymeric NPs interacted
with BLG in the inhibition process ranged from 5±1 nm to 35±5 nm. The height of the
fibrils generated after the methylated polymeric NPs interacted with BLG mostly ranged
from 8±1 nm to 12±1 nm, which was higher than the untreated BLG fibrils. Also, the
NPs generated during this process had similar width / diameter as described earlier, while
their height ranged from 15±1 nm to 20±2 nm.
Adamcik et al. described the structural formation of the BGL fibrils based on the
periodicity of the pitch in various fibrils observed in AFM obtained images. (65, 67)
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Figure 3-11 shows the longitudinal cross-section of the BLG fibrils analyzed with a
Nanoscale analyzer. Untreated BLG fibrils showed four types of periodicity (p) in the
pitch, such as 70±8 nm, 160±10 nm, 200±15 nm, and 320±20 nm (Figure 3-11 (a)). Three
of these four types of periodicities had fibrils height of 4±0.5 nm, 6±0.5 nm, and 8±1 nm,
which represent 2, 3, and 4 individual fibrils getting together in twisted formation.
However, one of the fibrils had a little different structural formation than the twisted
shape fibrils, and with a 10±1 nm height and periodicity of 320±20 nm, it formed more
helical-shaped fibrils. As these fibrils turned into helical shapes, their periodicity was half
of the obtained 320 nm.
Based on the obtained periodicities and fibril heights, 3D models representing all
the fibril structures are shown on the left side of Figure 3-11 (a). The untreated BLG
fibrils’ structural morphologies were consistent with already published reports. Figure 311 (b) shows the cross-section of the fibrils that formed after methylated polymeric NPs
interacted with BLG. These fibrils had different types of heights, but no distinct
periodicity could be observed in any of the fibrils. This indistinct periodicity may imply
that the methylated polymeric NPs treatment of BLG helped individual fibrils to compile
together with more internal structural induction, such as increased b-sheet, which
ultimately lead to the formation of a nanotube-type fibril structure. A 3D model is shown
in the right side of Figure 3-11 (b), representing the fibril nanotube.
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Figure 3-11. Longitudinal height profiles and pitch periodicities of (a) BLG (0.272 mM)
fibrils, and (b) methylated polymeric NPs treated BLG fibrils. 3D structures show the
possible structural formation for fibrils, based on the longitudinal height profile and the
fibrils’ pitch periodicities.
Based on the DLS and AFM analyzed data, a schematic representing possible
formations of fibrils and associated NPs during the fibrillation inhibition process is
shown in Figure 3-12.
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Figure 3-12. Schematic representations of protein fibrillation processes and inhibition,
using fluorinated and methylated polymeric NPs against BLG.
ATR-FTIR is widely used to analyze the transformations that occur in protein
secondary structures. (75, 92-94) Figure 3-13 shows the ATR-FTIR spectra of the
nanocomposites generated after the amyloid inhibition process, along with the fibrillated
and nonfibrillated BLG. Two amide peaks, amide I at 1725-1600 cm-1, and amide II at
1525-1550 cm-1, were visible in all four spectra, such as BLG, fibrillated BLG, 3F treated
composite NPs, nPM treated BLG fibrils and associated NPs. Another major peak at
1725 cm-1 was also visible in all spectra. Vibration in this region represents the
protonated carboxyl groups of aspartic and glutamic residues. (75)
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Figure 3-13. ATR-FTIR spectra of BLG (0.272 mM), BLG (0.272 mM) fibrils, 3F and
nPM NPs treated BLG (0.272 mM).
Increase in the intensity of this peak implies more exposure of the backbone
carboxyl groups, potentially through backbone cleavage. (75) The FTIR spectral zone
representing CH3 and CH2 (1300-1480 cm-1) showed the presence of additional peaks in
the fluorinated and methylated polymeric NPs treated BLG products, compared to both
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the fibrillated and nonfibrillated BLG. These additional peaks were due to the presence of
nPM and 3F functionality in the post inhibition process products. The presence of –CF
peak at 1250 cm-1 and Si-CH2-R peak at 1210 cm-1 increases the possibility of having the
combination of BLG and fluorinated silica particles present in the composite NPs.
The fibrillated BLG spectrum showed that the absorbance intensity of the two
amide peaks at 1625 cm-1 (amide I) and 1525 cm-1 (amide II) were reduced, but these two
amide regions widened in wavenumber, compared to the nonfibrillated BLG, indicating
structural transformation of BLG as fibrillation occurred. Also, increments in the
intensity of peak at 1725 cm-1 confirmed the fibril formation of BLG as structural
transition occurred. (75) The spectrum representing fibrils and associated NPs generated
after the interaction of BLG and methylated polymeric NPs showed that the absorbance
intensity reduced drastically in both the amide zones, and amide I peak at 1625 cm-1
broke into three smaller peaks. Also, the increments in the intensity of the protonated
carboxyl peak at 1725 cm-1 represented the presence of fibrillated BLG. Similarly, the
spectrum representing the nanocomposites generated after fluorinated polymeric NPs
interacted with BLG also showed reduction in two amide peaks, but unlike breaking into
smaller peaks, amide I peak at 1625 cm-1 shifted to 1650 cm-1. The transition in the major
peaks in the spectra can be concluded as a major conformational transformation in the
secondary structure during the fluorinated and methylated polymeric NPs treatment of
BLG.
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For better understanding of the possible conformational changes in the secondary
structures of BLG after the inhibition process, FTIR spectra in the amide zones were
deconvoluted. Secondary structures are shown as numbers in the amide I zone (1600 cm-1
to 1700 cm-1), and this zone was selected because it was observed as the most sensitive
part of the spectra, where possible conformation change may occur.

Figure 3-14. Deconvoluted ATR-FTIR spectra of BLG (0.272 mM), BLG (0.272 mM)
fibrils, 3F and nPM NP treated BLG (0.272 mM). Individual peaks between 1600 cm-1 to
1700 cm-1 are numbered.
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Figure 3-14 shows the individual deconvoluted peaks that represent different types of
protein secondary structures such as α-helix (1654±2 cm-1), β-sheet (1612-1650 cm-1 and
1691±2 cm-1), β-turn (1666-1687 cm-1), and 310-helix (1663±3 cm-1). (92, 94) All the
deconvoluted peaks for the secondary structures are shown in numbers in all the spectra
in Table 3-1.

Table 3-1. Deconvoluted components of the secondary structures of BLG (0.272 mM),
BLG (0.272 mM) fibrils, 3F and nPM treated BLG (0.272 mM) obtained from Figure 314.
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From Table 3-1, it can be observed that the a-helix structure disappeared after
the methylated polymeric NPs treated BLG, and it turned into random secondary
structure and 310-helical structure.
The secondary structures were identified from the deconvoluted spectra, and
individual spectral areas were calculated. Comparative data of the conformational change
of the secondary structures b-sheet and a-helix were calculated based on the % area of
individual peaks obtained from the spectra is shown in Figure 3-15.

Figure 3-15. Comparative β-sheet (a) and α-helix (b) % of BLG, fibrillated BLG, 3F and
nPM treated BLG. P value obtained after performing one-way ANOVA test. **, and ***
represent P value ≤ 0.01 and ≤ 0.001, respectively, obtained after performing one-way
ANOVA test among the samples.
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Analyzed data shows that β-sheet increased by 11 % and a-helix decreased by 9
% in the fibrillated BLG, compared to the nonfibrillated BLG. These increases in the β
structures were expected, since they are responsible for the formation of fibrils. Increased
b-sheet and decreased a-helix imply that α-helix is transformed into β structures.
The fibrils and associated NPs generated after interaction of methylated polymeric
NPs with BLG showed disappearance of the a-helix structure and 7 % reduction in the bsheet structure, which eventually converted to random secondary structures and 310helical structures. A different picture was observed with data obtained from the
fluorinated polymeric NPs treated BLG nanocomposites, where β-sheet decreased by 29
% and α-helix increased by 10 %, which confirmed the b-sheet induction by the
fluorinated polymeric NPs. Figure 3-15 shows the comparative plotting of the b-sheet %
(Figure 3-15 (a)) and α-helix % (Figure 3-15 (b)) in each individual case, with one-way
ANOVA analysis indicating that the observed conformation shifts are significant.
BLG reportedly has three potential binding sites for ligand binding: 1) internal bbarrel cavity, 2) surface hydrophobic pocket in a groove between α -helix and b-barrel,
and 3) outer surface near Trp19-Arg124. (95-100) To examine the binding mode of
fluorinated and methylated polymeric NPs at the active site of BLG and how they may
affect the conformation of BLG, docking simulations were carried out using AutoDock,
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but due to fluorinated and methylated polymeric NPs size constrains, only monomeric
hydrolyzed forms of both 3F and nPM or silanols were used.

Figure 3-16. Predicted modes of binding between (a) fluorinated and (b) methylated
silanol with BLG at the lowest binding energy. Hydrogen bonds are marked as a line of
green dots.
During the docking, a maximum number of 10 conformers were considered, and
the lowest energy conformation was used for further analysis. Docking results showed
that both 3F and nPM were located in the β-domain, as shown in Figure 3-16 (a), and (b).
On the basis of Figure 3-16, the interacting residues of possible binding patterns
and properties resulting from the bindings are listed in Table 3-2. The docking results
showed that fluorinated silanol binds to the surface of BLG by two hydrogen bond
interactions with GLU44. The predicted binding site for fluorinated silanol on BLG was
clustered around residues such as HIS161, SER21, TYR20, TYR42, GLU44 and VAL45.
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There were two hydrogen bonds between H3F and ILE, with the distance of 2.874 Å and
2.744 Å.

Table 3-2. Dock scores and summary of molecular interaction between fluorinated and
methylated silanols and BLG.

Similarly, the predicted binding site for methylated silanol on BLG was clustered
around residues such as GLN5, ALA139, LYS141, ALA142, and THR4. The docking
results showed that methylated silanol binds to the surface of BLG by one hydrogen bond
interactions, and these hydrogen bonds occurred between methylated silanol with GLN5,
with distance of 2.021 Å. 3F and nPM bonded with hydrophobic amino acids of BLG,
where the hydroxyl group acted as hydrogen bond donor. Thus, it can be concluded that
the interaction of the hydroxyl groups in the structure of fluorinated and methylated
polymeric NPs with BLG has a significant role in the binding process, which eventually
takes part in inhibiting and prohibiting the amyloid fibril process.

101
3.6 Conclusion
This study demonstrated the amyloid inhibition behavior of fluorinated and
methylated polymeric silane NPs against a globular protein, BLG. The hydrolysis and
condensation profiles of both silanes were determined using DLS, in order to control
particle size and reactivity. After initial confirmation of the amyloid inhibition capability
of fluorinated polymeric NPs by DLS and fluorescence data, detailed structural
information was obtained by AFM. The AFM-based study showed the complete
inhibition of amyloid fibrils growth by fluorinated polymeric NPs, but there was no
inhibition by methylated polymeric NPs. Later, ATR-FTIR study showed transformation
in the secondary structure of BLG during the inhibition process, where it showed that
decrease in b structures occurred due to interaction between fluorinated polymeric NPs
and BLG. Expectedly, the percentage of b structures increased during the interaction
between methylated polymeric NPs and BLG, since the AFM image showed that
methylated polymeric NPs promoted amyloid formation. Lastly, a molecular docking
study confirmed that free silanols were involved through hydrogen with protein residues
for both silanes. The successful amyloid inhibition ability of fluorinated polymeric NPs
showed the potential use of these NPs as nanotherapeutic agents against amyloid
diseases. In the future, a comprehensive study on the use of these fluorinated polymeric
NPs against various amyloid-based diseases should be explored.
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CHAPTER 4
AQUEOUS SYNTHESIS OF SUPERHYDROPHOBIC NANOPARTICLES AND
THEIR AMYLOID INHIBITION ABILITY

4.1 Abstract
Superhydrophobic silica nanoparticles (SHSN) were synthesized from fluorinated
(3F) and methylated (nPM) trimethoxy-silane precursors. This synthesis from
hydrophobic precursor silanes occurs through an acid hydrolysis followed by baseinitiated condensation, without the need for organic solvents. SEM and AFM analysis
reported that fluorinated SHSN were relatively monodisperse and smaller (250±30 nm),
compared with the methylated SHSN (500±200 nm). Water contact angles on both
fluorinated and methylated SHSN coated surfaces were > 150°. Amyloid inhibition
behavior of these SHSN against BLG showed that fluorinated SHSN could inhibit
amyloid fibrillation, whereas under the same conditions the methylated SHSN did not
inhibit BLG fibrillation.
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4.2 Introduction
A surface is considered superhydrophobic when it exhibits a water contact angle
larger than 150° and detachment or sliding angle lower than a 5° tilt of the surface.
Superhydrophobic surfaces have gained wide interest due to their low fouling, selfcleaning, and low friction properties. (1) Superhydrophobic surfaces have various
potential applications due to their anticorrosive, self-cleaning, antifogging, anti-icing,
drag reducing, oil-water separating, and water harvesting properties. (2-11) Nanoparticles
(NPs) with superhydrophobic properties can also be used as drug delivery vehicles and
therapeutic agents against the protein misfolding-based diseases. (12-14) Engineered
biocompatible NPs have shown great promise as therapeutic agents for amyloid-related
diseases, as they are capable of crossing the blood-brain-barrier (BBB). (15, 16) NPs can
both promote and inhibit protein aggregation by binding with proteins and trapping the
early intermediates. (17) N-isopropylacrylamide / N-tert-butylacrylamide, titanium oxide,
and quantum dots based NPs can promote the protein assembly into amyloid fibrils in
vitro, by assisting the nucleation process. (18-20) In contrast, other studies have
demonstrated that hydrophobic NPs, or NPs functionalized with hydrophobic molecules,
can inhibit the fibrillation process. (21-22) Cabaleiro-Lago et al. reported that copolymer
NPs of variable hydrophobicity inhibited the fibrillation of αβ (1-40). (17) Fluorinated
NPs are also potential inhibitors against the αβ fibrillation. (23) To investigate
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superhydrophobic NPs against amyloid formation, we have synthesized fluorinated and
methylated SHSN from alkyl- and fluoro-silane precursors.
Conventional synthesis of SHSN follows the Stöber method, where hydrophilic silica
nanoparticles (HSN) are first synthesized, isolated, purified, and then functionalized
using the hydrophobic silanes. (8, 9) This multi-step method for synthesizing SHSN is
carried out using alcohol as the solvent, and it requires addition of a strong base. Here,
we present an aqueous method to synthesize SHSN from a single precursor, where
precursors are initially hydrolyzed in a mild acidic condition before a catalyst (NH4OH)
is added to initiate condensation. This method requires only a single isolation and
washing step, providing a more sustainable and environmentally friendly approach to
produce SHSN. Our synthesized SHSN were tested against the fibrillation of BLG. The
size and shapes of the SHSN were assessed using DLS and AFM, and
superhydrophobicity was confirmed by static water contact angle.

4.3 Experimental procedure
Materials
3,3,3-trifluoropropyl trimethoxy silane (3F, > 95 % purity, MW = 218.3, d =
g/ml), and n-propyltrimethoxy silane (nPM, > 95 % purity, MW = 164.3, d = 0.94 g/ml)
were purchased from Gelest, Inc. (Morrisville, PA). 50 % (w/w) NH4OH was purchased
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from Fisher Scientific. Muscovite mica was purchased from SPI supplies for the AFM
study (PA, USA); AFM tips were obtained from TED Pella Inc., CA (TAP300AL-G-50).
Synthesis of fluorinated and methylated SHSN
0.4 M nPM and 3F were hydrolyzed at pH 3.0 in glass vials at room temperature.
Once nPM and 3F were hydrolyzed, 0.05 M NH4OH was added to generate NPs with
different sizes. Reactions were continued until stable white NPs were visible. Once the
NPs were formed, both nPM and 3F solutions with newly formed NPs were centrifuged;
and then the NPs were separated from the supernatant and washed with DI water, and
freeze-dried overnight.

Characterization of fluorinated and methylated SHSN
SEM images were taken using a FEI Quanta FEG 650 equipped with an Oxford
X-Max Energy Dispersive X-ray spectroscope (EDS) housed in the Microscopy Core
Facility at Utah State University. Samples were imaged with 20 kV accelerating potential
without conductive coatings. AFM images were taken using a Nanoscope III Bioscope
(Digital Instrument, Inc.) in tapping mode. 100 µl samples were dropped on freshly
cleaved mica surfaces, then gently washed with DI water, and air-dried before taking
AFM images.
The hydrophobicity of the NPs was determined using water contact angle. The
contact angle was measured with a VCA Optima digital contact angle instrument (AST
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products, Billerica, MA). 10 µl DI water was dropped on NP thin films prepared on
double-stick tape over glass slides, and then the contact angle was measured.
The NP FTIR spectra were collected using a Varian 660-IR with a horizontal
single reflection Pike Technologies MIRacle attenuated total reflectance (ATR) unit,
fitted with a ZnSe crystal. 100 µl samples were drop cast on the ZnSe crystal of the ATR
platform, and air-dried before taking the reading. Readings were taken after averaging 20
scans over the range of 600 to 1800 cm-1 with a resolution of 1 cm-1. Prior to each
reading, a background scan was acquired. The spectra provide signatures of the pure NPs
for future works involving mixed alkyl-fluoro-NPs and NP-protein interactions.
Interaction of fluorinated and methylated SHSN with BLG
Fluorinated and methylated SHSNs were reacted against BLG at pH 2.0 and room
temperature for 10 min, and then the fibrillation process was tested at 85°C for 5 h. Next,
samples were cooled down to room temperature again, using ice bath, and resulting
protein fibrils were investigated using AFM, operating in tapping mode in air.

4.4 Results and Discussion
SEM images of fluorinated and methylated SHSN are shown in Figure 4-1 (a) and
(b), respectively. Average size of the fluorinated and methylated SHSN were 250±30 nm
and 500±200 nm, respectively.
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Figure 4-1. SEM images of (a) fluorinated SHSN and (b) methylated SHSN

These size DIstributions were further confirmed using AFM image analysis
shown as 3D structures in Figure 4-2. Both SEM and AFM showed that the methylated
NPs were larger in size, compared to the fluorinated NPs, and the fluorinated NPs were
highly monodispersed, as compared to the methylated NPs.

Figure 4-2. AFM images of (a) fluorinated SHSN, and (b) methylated SHSN.

117
The presence of the fluorine functionality in the fluorinated NPs was confirmed,
as ATR-FTIR-spectra shows the –CF stretching at 1250 cm-1, 840 cm-1, and 990 cm-1
(Figure 4-3). Presence of CH3, and CH2 bending along with the Si-O-Si, and Si-CH2-R
stretching peaks confirmed the hydrophobic functionality on both the SHSN surfaces.

Figure 4-3. ATR-FTIR spectra of (a) fluorinated SHSN (red, top), and (b) methylated
SHSN (black, bottom).
Superhydrophobicity was confirmed by water contact angles on the fluorinated
and methylated SHSN-coated surfaces. Figure 4-4 (a) and (b) show that the water contact
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angles are >150° on both the fluorinated and methylated SHSN-coated surfaces, and
confirm the superhydrophobic behavior of both SHSNs.

Figure 4-4. Static water contact angle (a) fluorinated SHSN, and (b) methylated SHSN
prepared as thin films on double-stick tape.
When these SHSN were used against the fibrillation of BLG, the fluorinated
SHSN were capable of inhibiting the amyloid formation, with only a few fibrils being
observed in the AFM image representing the fluorinated SHSN-treated BLG (Figure 4-5
(a)). In the same AFM image, significant aggregated features are observed, which may be
the unreacted NPs or NP-BLG composites formed after the NPs and BLG interaction.
However, methylated SHSN did not inhibit the fibrillation of BLG, as Figure 4-5 (b)
shows numerous fibrils formed during the inhibition process. This distinct inhibition
behavior of fluorinated and methylated SHSN proves that the amyloid inhibition is
discretely affected, due to the presence of the fluorine functionality.
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Figure 4-5. AFM images of amyloid inhibition of BLG by (a) fluorinated SHSN, and (b)
methylated SHSN.
4.5 Conclusion
The successful aqueous synthesis of the superhydrophobic NPs from both
fluorinated and methylated silane precursors showed a new, environmentally friendly and
simple approach to synthesize the SHSN, without using a orthosilicate precursor,
followed by surface modification with the hydrophobic silane as a capping layer. These
SHSN have applications as discrete particles for tuning protein secondary structure, as
well as composite properties when assembled as thin films, rendering the surface
superhydrophobic. The facile synthesis of the NPs in aqueous solvents offers this
approach suitable for biological interactions. The unique amyloid inhibition ability of the
fluorinated SHSN, contrasted with the methylated SHSN, underscores the role of the
fluoro-groups in this activity. Both NPs exhibited a similar surface energy, based on
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sessile water droplet contact angles, thus the protein structure-tuning behavior is not
merely a function of surface energy. These results suggest the potential of fluorinated
SHSN to be used in the treatment of protein misfolding-based diseases as well as in
biotechnology applications where protein aggregation and assembly must be controlled.
The aqueous synthesis process from a single precursor is an economically and
environmentally viable approach to scaling this technology for superhydrophobic
nanoparticle production.
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CHAPTER 5
SUPERHYDROPHOBIC SILICA NANOPARTICLES AS CARRIERS FOR
HYDROPHOBIC SMALL DRUG MOLECULES

5.1 Abstract
Two hydrophobic therapeutic biomolecules, curcumin and quercetin were
successfully loaded on fluorinated and methylated superhydrophobic silica nanoparticles
(SHSN). DLS and SEM were used to measure the sizes of the curcumin and quercetinloaded nanoparticles (NPs). Hydrodynamic radius (Rh) measured by DLS showed that
after loading curcumin, the Rh of the fluorinated SHSN increased from 135 nm to 165
nm, and the Rh of the methylated SHSN increased from 250 nm to 308 nm. Similarly,
after loading quercetin, Rh of the SHSN increased from 135 nm to 175 nm, but the Rh of
the methylated SHSN increased from 250 nm to bimodal sizes of NPs, such as 134 nm
and 380 nm. This bimodal distribution of quercetin-loaded methylated SHSN was later
confirmed by DLS study. Curcumin loading in both fluorinated and methylated NPs and
quercetin loading in methylated NPs did not change the spherical shape of the
corresponding NPs, but quercetin loading in fluorinated NPs deformed the shape of the
NPs. Hydrophobicity of the fluorinated SHSN decreased after loading curcumin and
quercetin, as water contact angle decreased from 151° to 136° and 142°, respectively.
Similarly, hydrophobicity of the methylated SHSN also decreased after loading of
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curcumin and quercetin, as water contact angle decreased from 155° to 142° and 145°,
respectively. ATR-FTIR spectra confirmed the conjugation of the curcumin and quercetin
in the NPs. Release kinetic study showed a quick initial burst of curcumin and quercetin
release within 1 to 1.5 h; while cumulative releases reached their plateau after 5 h for
curcumin and 7 to 10 h for quercetin, from both fluorinated and methylated NPs.

5.2 Introduction
Biomolecules such as curcumin and quercetin recently have attracted the attention
of the scientific community, due to their astonishing antioxidant, anti-inflammatory,
anticarcinogenic, chemopreventive, antiangiogenic, anti-diabetic, antiviral, and
antibacterial properties. (1-10) Extensive research has been carried out on both quercetin
and curcumin around the globe, to demonstrate their great potential as therapeutic agents,
and both have shown the way toward clinical trials for a variety of diseases. (11-14)
Despite the wide spectrum of beneficial properties, the use of both of these biomolecules
in the commercial field is limited, because of their hydrophobic nature. (15-18)
Hydrophobicity has been the major obstacle in their progress from being used as a drug
in the lab to clinical studies. In recent years, researchers have focused on exploring the
potential applications of these hydrophobic small molecules as drugs, with the aid of
modern nanotechnologies. (19-21) Loading or conjugating these molecules in NPs,
liposomes, micelles, soy protein isolate, oil body encapsulation, cyclodextrin, chitosan,
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and phospholipid complex has proven to enhance the dispersibility and bioactivity of
these molecules for clinical trials. (22-30) Conjugating or loading the drug molecules in
NPs has become increasingly remarkable, because it offers numerous benefits, including
ease of handling, enhanced stability, controlled release, and enhanced bioavailability and
efficacy. Inorganic silica, alumina, and titanium-based NPs are widely used as drug
carriers for their compatibility in biological systems. (31-36). Superhydrophobic silica
nanoparticles (SHSN) have the potential to be used as drug delivery vehicles for the
active drug molecules. Conventional synthesis of drug-loaded SHSN includes the initial
synthesis of hydrophilic silica NPs, following the Stöber method, followed by isolation,
purification of the NPs, and then functionalizing them, using a hydrophobic silane;
followed by further isolation, purification, and drug loading steps. (37, 38) This multistep
method is carried out using alcohol as a solvent, and it requires the addition of a strong
base. In previous chapters, we have described a new one-step aqueous synthesis of
SHSN, which opens the door to loading or conjugating small hydrophobic drug
molecules in SHSN, in an environmentally friendly and biocompatible system.
This study aimed to synthesize quercetin and curcumin-loaded / conjugated
superhydrophobic silica NPs in an environmentally friendly aqueous system, with only a
single isolation and washing step. This effective and stable incorporation of drug
molecules in the SHSN can lead to other hydrophobic drug molecules being integrated in
the NP-based drug delivery vehicles.

126
5.3 Experimental procedure
Materials
3,3,3-trifluoropropyl trimethoxy silane (3F, > 95 % purity, MW = 218.3, d = 1.14
g/ml), and n-propyltrimethoxy silane (nPM, > 95 % purity, MW = 164.3, d = 0.94 g/ml)
were purchased from Gelest, Inc. (Morrisville, PA). 50 % (w/w) NH4OH was purchased
from Fisher Scientific. Muscovite mica was purchased from SPI supplies for the AFM
study (PA, USA); AFM tips were obtained from TED Pella Inc., CA (TAP300AL-G-50).
Ethanol was obtained from Pharmco-AAPER (Brookfield), and dimethyl sulfoxide
(DMSO) (99.5 %) was obtained from Sigma-Aldrich (MO, U.S.A). Quercetin hydrate
was purchased from Acros Organics (Morris Plains, NJ, USA), and curcumin was
purchased from Sigma-Aldrich (MO, U.S.A).
Synthesizing silica-drug molecule composite
Hydrolysis of 3F (0.4 M) and nPM (0.4 M) were performed at pH 3.0 separately,
in glass vials in DI water. 4 mg of quercetin and curcumin were separately dissolved in 2
ml ethanol to have 2 mg/ml solution, and then added to the hydrolyzed silanes. Next,
quercetin and curcumin-loaded silica NPs were synthesized, following the Stöber
method. (39) The overall experimental process is shown in Figure 5-1. Once the synthesis
was completed, as white colloidal particles appeared, NPs were centrifuged, washed, and
lyophilized for further characterization and drug release study. Note: samples were taken
before lyophilization, to perform DLS study.
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Figure 5-1. Flow chart and corresponding images of loading small drug molecules in
HSNs.
Characterization of drug-loaded silica nanocomposite particles
The hydrodynamic radii (Rh) of the curcumin and quercetin-loaded or unloaded,
fluorinated and methylated NPs were analyzed using DLS (DynaPro NanoStar, Wyatt
Technology Corporation, Santa Barbara, CA), with a 658 nm laser. DLS measurements
were taken using a quartz cuvette (JC-426, 1 µl) filled with 1 ml aqueous solution
containing drug-loaded and unloaded NPs. Prior to the Rh measurement, NPs in the
aqueous solutions were diluted 100 times.
SEM was performed with a FEI Quanta FEG 650 equipped with an Oxford XMax Energy Dispersive X-ray Spectroscope (EDS) housed in the Microscopy Core
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Facility at Utah State University. Samples were imaged with 20 kV accelerating
potential, without conductive coatings. AFM images were taken using a Nanoscope III
Bioscope (Digital Instrument, Inc.) in tapping mode. 100 µl samples were dropped onto
freshly cleaved mica surfaces, and then gently washed with DI water and air-dried before
taking AFM images. The water contact angle was measured with a VCA Optima digital
contact angle instrument (AST products, Billerica, MA) on the quercetin and curcuminloaded and non-loaded HSN kept on a double-stick tape surface over glass slides, using
10 µl sessile drops of DI water. The chemical bonding between silica and drug molecules
were analyzed by FTIR, using a Varian 660-IR with a horizontal single reflection Pike
Technologies MIRacle attenuated total reflectance (ATR) unit, fitted with a ZnSe crystal.
100µl samples were drop casted on the ZnSe crystal of the ATR platform, and air-dried
before taking the reading. Readings were taken after averaging 20 scans over the range of
600 cm-1 to 1800 cm-1, with a resolution of 1 cm-1. Prior to each reading, a background
scan was acquired.
Drug release kinetics study
Drug release kinetic study was performed in a PBS buffer solution (pH 7.0) for 4
days. 0.5 mg/ml curcumin and quercetin-loaded, fluorinated and methylated SHSN were
added in 1 ml PBS solution and shaken (200 rpm) at 37°C, kept in an incubator. All
samples were covered with aluminum foil during the incubation period.
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Figure 5-2. Calibration curve for (a) curcumin, and (b) quercetin measured in 50 %
ETOH and 50 % DMSO, respectively.
After being centrifuged at 14 k for 10 min, 100 µl samples were collected from
the supernatant of each vial at the desired time, and added in 100 µl DMSO and ETOH in
a 96-well plate to measure quercetin and curcumin absorbance, respectively. Absorbance
data were taken at 370 nm and 420 nm wavelengths for quercetin and curcumin,
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respectively. Prior to the analysis of release kinetics of both curcumin and quercetin,
calibration curves were obtained, as shown in Figure 5-2 (a) and (b) for curcumin and
quercetin, respectively. For the absorbance reading of curcumin samples 50 % ETOH,
and for quercetin samples 50 % DMSO solutions were used.

5.4 Results and Discussion
Hydrodynamic radius (Rh) of curcumin and quercetin loaded on both fluorinated
and methylated NPs are shown in Figures 5-3 and 5-4, respectively. Rh size of the
curcumin loaded fluorinated NPs were larger (165±18 nm), compared to the unloaded
fluorinated NPs (135±10 nm) shown in Figure 5-3 (a). Similarly, the Rh of the curcuminloaded methylated NPs were larger (308±35 nm), compared to the unloaded NPs (250±22
nm) shown in Figure 5-3 (b).
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Figure 5-3. Hydrodynamic radius (Rh) of curcumin loaded (a) fluorinated NPs, and (b)
methylated NPs.
Quercetin-loaded fluorinated and methylated NPs followed a similar trend as
curcumin-loaded NPs. Figure 5-4 (a) shows that quercetin-loaded fluorinated NPs were
larger (175±8 nm), compared to the unloaded NPs (135±10 nm). But interestingly, a
bimodal distribution of NPs was observed in the case of quercetin-loaded methylated
NPs, as two sizes of 134±5 nm and 380±20 nm can be observed in Figure 5-4 (b).
Increase in the sizes of the drug-loaded fluorinated and methylated NPs indicates the
successful loading or conjugation of the drug molecules.
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Figure 5-4. Hydrodynamic radius (Rh) of quercetin-loaded (a) fluorinated NPs, and (b)
methylated NPs.
For further confirmation, SEM images were obtained, as shown in Figures 5-5
and 5-6. SEM images confirmed the increase of NP sizes after loading the drug
molecules. Figure 5-5 (a) and (b) show the curcumin-loaded and unloaded fluorinated
NPs. Curcumin-loaded fluorinated NPs (Figure 5-5 (a)) showed increase in size,
compared to the unloaded NPs (Figure 5-5 (b)), as their diameter increased from 250±20
nm to 290±5 nm, which is consistent with the DLS-obtained sizes.
An opposite trend can be observed in the curcumin-loaded methylated NPs’ sizes,
as curcumin-loaded NPs decreased to 450±50 nm (Figure 5-5 (d)) from unloaded NPs of
540±50 nm (Figure 5-5 (c)). The shapes of the NPs didn’t change after curcumin was
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loaded in the fluorinated NPs, rather it remained smooth and spherical as it was in the
unloaded NPs. However, after curcumin was loaded in the methylated NPs, the shape of
the NPs no longer remained spherical, rather it turned into egg-shaped structures.

Figure 5-5. SEM images of (a) fluorinated NPs, (b) curcumin-loaded fluorinated NPs, (c)
methylated NPs, and (d) curcumin-loaded methylated NPs.
Quercetin-loaded fluorinated NPs also increased in size (290±10 nm) (Figure 5-6
(a)), compared to the unloaded NPs (250±20 nm) (Figure 5-6 (b)); and this increase is
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consistent with the DLS-obtained data. However, fluorinated NPs were deformed,
unsmooth in shape, after quercetin was loaded.

Figure 5-6. SEM images of (a) fluorinated NPs, (b) quercetin-loaded fluorinated NPs, (c)
methylated NPs, and (d) quercetin-loaded methylated NPs.
Quercetin-loaded methylated NPs (Figure 5-6 (d)) didn’t change in shape,
compared to the unloaded NPs (Figure 5-6 (c)); rather, bimodal NPs such as (235±5 nm
and 750±10 nm) were observed, compared to the unloaded NPs (540±50 nm) shown in
Figure 5-6 (c). This bimodal distribution is consistent with the DLS-analyzed sizes.
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The transformation in the hydrophobicity after loading the drug molecules in
fluorinated and methylated NPs’ surfaces was studied using water contact angles, as
shown in Figure 5-7 (a) and (b), respectively. Curcumin loading decreased the
hydrophobicity in both fluorinated and methylated NPs, as the water contact angle
dropped from 151°±1° to 136°±2° on the fluorinated NPs and 155°±1° to 142°±1° on the
methylated NPs’ surfaces. Similarly, quercetin loading also decreased the water contact
angle on the NPs’ surfaces, as water contact angle dropped from 151°±1° to 142°±2 on
the fluorinated NPs and 155°±1° to 145°±1 on the methylated NPs’ surfaces.

Figure 5-7. Static water contact angles measured on curcumin and quercetin-loaded (a)
fluorinated NPs, and (b) methylated NPs’ surfaces.
ATR-FTIR spectra of the curcumin and quercetin-loaded NPs confirmed the
presence of these two drug molecules on the surface of both the fluorinated and
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methylated NPs. ATR-FTIR spectra of curcumin-loaded fluorinated and methylated NPs
are shown in Figure 5-8 (a) and (b), respectively. The presence of the aromatic
functionality from 1490 cm-1 to 1690 cm-1 confirms the presence of curcumin on both the
fluorinated and methylated NPs’ surface. The presence of fluorine functionality was
confirmed as the -CF bending stretch was observed at 1250 cm-1 and 840 cm-1.

Figure 5-8. ATR-FTIR spectra of curcumin-loaded (a) fluorinated NPs, and (b)
methylated NPs.
Similarly, quercetin loading in both fluorinated and methylated NPs was
confirmed in the ATR-FTIR spectra shown in Figure 5-9 (a) and (b), respectively, with
the presence of the peak around the aromatic zones being 1490 cm-1 to 1690 cm-1.
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Figure 5-9. ATR-FTIR spectra of quercetin-loaded (a) fluorinated NPs, and (b)
methylated NPs.
After the successful loading of curcumin and quercetin molecules in both
fluorinated and methylated NPs, release kinetics of these drug molecules were also
studied. The release kinetics of curcumin from the fluorinated and methylated NPs in the
PBS solution showed that from both NPs, a quick burst of curcumin release occurred
within 60±10 min, and then cumulative release reached the plateau after 300±10 min.
However, only 20 % and 12 % of curcumin were released from the fluorinated and
methylated NPs, respectively, after reaching the plateau (Figure 5-10).
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Figure 5-10. Release kinetics of curcumin from (a) fluorinated NPs, and (b) methylated
NPs.
Unlike the curcumin release, quercetin release was slower from both fluorinated
and methylated NPs, as shown in Figure 5-11 (a) and (b), respectively. After an initial
burst of quercetin release within 100±20 min, a total of 32 % quercetin was released from
the fluorinated NPs over 420±20 min, and 40 % of quercetin was released from the
methylated NPs over 600±30 min, after reaching the plateau.
Ethanol dissolved curcumin and quercetin initially were dissolved in aqueous
solution at pH 3.0, and later condensed to form NPs in basic solution (at pH ~ 9.5 to
10.0), by adding NH4OH. Although curcumin is expected to be stable at a pH near 10.0,
curcumin may be degraded at such high pH, which may reduce the curcumin’s efficacy
as a drug, as well as its loading efficiency. Nevertheless, the curcumin loading and
release was a proof of concept, along with that of quercetin. The possible degradation
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may be mitigated by the presence of the silane molecules, which can stabilize compounds
(e.g. enzymes are encapsulated in silane porous glasses and are more stable against
denaturing conditions).
The higher release % of quercetin from fluorinated and methylated NPs,
compared to curcumin, means that these NPs are relatively better drug delivery vehicles
for quercetin. As the time of the optimum release of curcumin and quercetin varies, they
can be suitable to be used in different biological systems where faster or slower drug
release is needed.

Figure 5-11. Release kinetics of quercetin from (a) fluorinated NPs, and (b) methylated
NPs.
5.5 Conclusion
In this study, we successfully loaded two hydrophobic drug molecules, curcumin
and quercetin, on fluorinated and methylated SHSN in a simple and environmentally
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friendly aqueous system. The loading or conjugation of both the molecules was
confirmed using different analytics tools such as DLS, AFM, and ATR-FTIR. The release
kinetics of the drug molecules showed distinct behavior, as curcumin release was quicker
and lesser than the quercetin release. Further study on the effect of the drug-loaded NPs
against the biological cells could reveal the efficiency of these drug-loaded NPs.
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CHAPTER 6
SILICA AND SPIDER SILK-BASED NANOCOMPOSITES SYNTHESIS

6.1 Abstract
This study introduced a simple and environmentally friendly method to synthesize
silica and spider silk protein-based nanocomposites. Prior to synthesis of the
nanocomposites, spider silk protein and silica precursors were dissolved and mixed in
aqueous solution, using microwave technology. Both SEM and AFM images showed that
the synthesized fluorinated spider silk-silica nanocomposites were a mixture of two types
of spherical NPs with the size < 100 nm and > 300 nm attached to each other. However,
methylated spider silk-silica nanocomposites were nanoaggregates with a mixture of
irregular-shaped nanospheres with the sizes < 200 nm. Deconvoluted ATR-FTIR spectra
confirmed the occurrence of conformational changes in the spider silk proteins during
their integration with fluorinated and methylated silica to form the nanocomposites. Total
amount of b structures increased by 10% in the spider silk-methylated silica
nanocomposites, compared to the spider silk protein, but decreased by 28% in the spider
silk-silica nanocomposites. Increased b structures can enhance the strength of the spider
silk and overall nanocomposites.
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6.2 Introduction
Protein-based composite materials have vast applications in biomedical fields
such as immunology, cancer research, and drug delivery. (1-4) These composite materials
are also useful in material science areas such as self-assembled materials, quantum dot
bioconjugates, sensors, and inorganic materials synthesis. (5-11) Silica particles are
widely used in industry, medicine, and nanotechnology (12, 13); and silica-based
biomaterials have potential applications in tissue engineering and drug delivery systems.
(14) Recombinant spider silk protein (rSSP) is a promising biomaterial with huge
potential in textiles, and in the biomedical and manufacturing industry, in the form of
fibers, films, hydrogels, lyogels, and adhesives. (15-21) Recently, spider silk-based
materials have shown great promise to attach and proliferate fibroblast cells. (22-27)
In the earlier chapters, we have shown that hydrophobic n-propyltrimethoxy
silane (nPM) and 3,3,3-trifluoropropyl trimethoxy silane (3F) both can induce the
secondary structures of the protein in their hydrolyzed state, and afterward, composite
particles consisting of protein and silica can be formed in the condensation process. Thus,
we hypothesize that nPM and 3F can induce spider silk proteins in their hydrolyzed state,
and nanocomposites consisting of spider silk and silica can be synthesized by condensing
the dissolved spider silk and nPM / 3F mix. The objective of this study was to synthesize
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spider silk-silica-silica nanocomposites from an aqueous mix of nPM / 3F and spider silk
protein.
We have successfully synthesized a new type of spider silk-silica nanocomposites
from spider silk and an nPM / 3F-mix aqueous solution. The synthesized spider silk-silica
nanocomposites have improved properties due to the controlled growth of nanoscale
organic-inorganic interfaces and composite structural features. Our synthesized
nanocomposites can be used to optimize the mechanical function and stability of
biomaterials. These nanocomposites also can be used in immunology, cancer research,
drug delivery devices, and biosensors.

6.3 Experimental procedure
Materials
3,3,3-trifluoropropyl trimethoxy silane (3F, > 95 % purity, MW = 218.3, d = 1.14
g/ml) and n-propyltrimethoxy silane (nPM, > 95 % purity, MW = 164.3, d = 0.94 g/ml)
were purchased from Gelest, Inc. (Morrisville, PA). 50 % (w/w) NH4OH was purchased
from Fisher Scientific. Muscovite mica was purchased from SPI supplies for AFM study
(PA, USA); and AFM tips were obtained from TED Pella Inc., CA (TAP300AL-G-50).
Two different types of rSSP protein, major ampullate silk protein rMaSp1 and major
ampullate silk protein rMaSp2, were purified from the milk of transgenic goats through
tangential flow filtration, precipitation, and washing.
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Synthesis of spider silk-silica nanocomposites
At first, 3F (0.4 M) and nPM (0.4 M) were hydrolyzed at pH 3.0 in aqueous
media in separate vials. Two rSSP proteins (rMaSp1and rMaSp2) were mixed in a ratio
of 50:50 and added in the H3F and HnPM media separately. These mixed solutions were
then microwaved (Haier microwave (700 W)) for 8 seconds for 4 times in a tightly closed
glass vial to dissolve the rSSPs. In between every cycle of microwave heating, 30 sec
breaks were taken.
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Figure 6-1. Schematic of Experimental procedure of the spider silk and 3F / nPM
nanocomposite materials.
Once the temperature reached 130°C, all rSSPs were dissolved in the aqueous
silane media. Hot and dissolved rSSPs in silane aqueous solutions were then cooled down
to 23°C, using ice water bath. Then, NH4OH was added to these rSSPs mixed solutions,
following the Stöber method, to synthesize silica-spider silk nanocomposite materials.
Synthesized composite materials were centrifuged and washed two times in DI water
before they were lyophilized overnight. The experimental schematic is shown in Figure
6-1.
Characterization of spider silk-silica nanocomposites
Dried nanocomposite materials were analyzed using image analysis tools such as
SEM, and AFM to determine their sizes and shapes. SEM was performed with a FEI
Quanta FEG 650 equipped with an Oxford X-Max Energy Dispersive X-ray
Spectroscopy (EDS) housed in the Microscopy Core Facility at Utah State University.
Samples were imaged with 20 kV accelerating potential without conductive coatings.
AFM images were taken using a Nanoscope III Bioscope (Digital Instrument, Inc.) in
tapping mode. 100 µl samples were dropped on freshly cleaved mica surfaces, then
gently washed with DI water, and air-dried before taking AFM images.
Bonding between spider silk protein (rSSP) and both fluorinated and methylated
silica were analyzed by FTIR using a Varian 660-IR with a horizontal single reflection
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Pike Technologies MIRacle attenuated total reflectance (ATR) unit, fitted with a ZnSe
crystal. 100 µl samples were drop cast on the ZnSe crystal of the ATR platform and airdried before taking the reading. Readings were taken after averaging 20 scans over the
range of 600 cm-1 to 1800 cm-1, with a resolution of 1 cm-1. Prior to each reading, a
background scan was acquired. The ATR-FTIR spectra were later deconvoluted, to
analyze the transformation in the secondary structures of spider silk protein.

6.4 Result and Discussion
Figure 6-2 shows the SEM images of spider silk-silica nanocomposites along with
the fluorinated and methylated silica NPs. Spider silk-methylated silica nanocomposites
shown in Figure 6-2 (b) were in aggregated or clogged form. These spider silkmethylated silica nanocomposites were built on smaller (<200 nm) nanoparticulates with
irregular-shaped spheres (Figure 6-2 (b), compared to the monodispersed methylated NPs
(540±50 nm) (Figure 6-2 (a)).
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Figure 6-2. SEM images of (a) methylated silica NPs, (b) spider silk-methylated
nanocomposites, (c) fluorinated silica NPs, and (d) spider silk-fluorinated
nanocomposites.
Spider silk-fluorinated silica nanocomposites (Figure 6-2 (d)) consisted of two
types of particles, NPs with size of <100 nm and >300 nm. These bimodal NPs were
attached to each other to form the nanocomposites, unlike the fluorinated NPs where NPs
were monodispersed with the size of 250±20 nm (Figure 6-2 (c)).
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Figure 6-3. AFM images (a) methylated silica NPs, (b) fluorinated silica NPs, (c) spider
silk-methylated nanocomposite, and (d) spider silk-fluorinated nanocomposites.
3D images of the nanocomposites obtained from the AFM further confirmed these
characteristics of the spider silk-methylated silica nanocomposites (Figure 6-3 (b)) and
spider silk-fluorinated nanocomposites (Figure 6-3 (d)), along with the methylated and
fluorinated silica NPs in Figure 6-3 (a) and Figure 6-3 (c), respectively.
ATR-FTIR spectra (Figure 6-4) showed some major conformational changes in
the amide I zone (1575 cm-1 to 1725 cm-1) of spider silk protein within the spider silkmethylated nanocomposites (SS-nPM) and the spider silk-fluorinated nanocomposites
(SS-3F).
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Figure 6-4. ATR-FTIR spectra of methylated silica NPs (nPM-NPs), fluorinated silica
NPs (3F-NPs), spider silk-methylated silica nanocomposites (SS-nPM), and spider silkfluorinated silica nanocomposites (SS-3F). SSP and SSW represent the spectra for the
spider silk in powder and spider silk in aqueous states.
Figure 6-4 also includes spectra for methylated silica NPs (nPM-NPs), fluorinated
silica NPs (3F-NPs), spider silk in powder (SSP), and aqueous states (SSW). Other than
amide I zone, other bending and stretching peaks were shown in the respected spectra.
Spectra representing 3F-NPs and SS-3FC, showed –CF peaks at 840 cm-1, 1020 cm-1, and
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1260 cm-1. Peaks representing Si-O-Si (800 cm-1, 1060 cm-1, and 1100 cm-1), and Si-CH2R (1210 cm-1) were visible in all the spectra, SS-nPM, SS-3F, nPM-NPs, and 3F-NPs,
confirming the integration of the spider silk in the nanocomposites. Also, the peaks for
CH3, CH2 (1320-1450 cm-1) and –CH (900 cm-1) were visible in all the spectra, including
SSP and SSW. Later, spectra were deconvoluted, to quantify the transformation in their
secondary structures in the nanocomposites in the amide I zone.
The deconvoluted FTIR spectra of SSP, SS-nPM, and SS-3F are shown in Figure
6-5 (a), (b) and (c), respectively. Figure 6-5 (d) shows the quantified secondary structure
% in the corresponding spider silk proteins. In SS-3F, b-sheet was reduced by 18 % and
b-turn reduced by 10 %, compared to the % of these secondary structures in SSP.
However, a new secondary structure, a 310-helix appeared in SS-3F spectra, and this 310helix was 35 % of the total secondary structures available in SS-3F.
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Figure 6-5. Deconvoluted ATR-FTIR spectra of (a) spider silk powder (SSP), (b) spider
silk-methylated silica NPs (SS-nPM), (c) spider silk-fluorinated silica NPs (SS-3F), and
(d) conformational change in secondary structures of BLG.
An opposite trend was observed in the secondary structures of the spider silk in
SS-nPM, where both b structures (sheet and turn) increased. In these nanocomposites, bsheet increased by 3 % and b-turn increased by 7 %. These patterns of conformational
changes in the secondary structures of SSP are consistent with conformational changes
observed in BLG protein, described in Chapter 3.
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6.5 Conclusion
We successfully synthesized spider silk-fluorinated and methylated
nanocomposites. SEM and AFM images showed that the integration of spider silk protein
with both fluorinated and methylated silica resulted in non-spherical nanocomposites
with distinct morphologies, contrasted with the control images of pure silanes. Strong
amide I and II peaks in the ATR-FTIR spectra further confirmed the integration of the
spider silk protein in the nanocomposites. Deconvoluted ATR-FTIR spectra showed
increased b structures in SS-nPM and decreased b structures in the SS-3F. SS-nPM can
be potentially stable against organic solvent, water, and strong acid and bases, due to the
assembly of highly stable b-sheets with high mechanical properties. Also, aqueous
synthesis of these nanocomposite materials makes them suitable for integration with
living tissues. These hybrid silica-protein structures have the potential to exhibit unique
biological activities, which will make them suitable for versatile biomedical applications.
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CHAPTER 7
HYDROPHOBIC SILANE-MODULATED SPIDER SILK FILMS

7.1 Abstract
Hydrophobic silane-modulated spider silk protein-based films were prepared in an
aqueous system. Hydrophobicity was higher on the silane-modulated spider silk film
surface, as water contact angle increased to 98° from 82° on the unmodulated spider silk
film surface. The presence of the methylated functionality in the silane-modulated films
was confirmed by ATR-FTIR spectra. The AFM-analyzed images showed that surface
roughness was higher on the silane-modulated spider silk films (9.83 nm), compared to
the unmodulated spider silk films (5.23 nm), which enhances their applicability in the
biomedical field.

7.2 Introduction
Recombinant spider silk protein (rSSP) fibers have a variety of applications in
textiles, and in the biomedical and manufacturing industries. (1−10) The extraordinary
mechanical strength of rSSP comes from its β-sheet-dominated secondary structures. (11)
Along with the production of fibers, significant efforts have been made to investigate the
alternative forms of rSSP, such as films, hydrogels, lyogels, and adhesives. (2−4, 12-14)
rSSP-based films have been studied for their biomedical applications such as attachment
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of fibroblasts, osteoblast-like cells, and skin cells. (7−11, 15) These rSSP films also have
shown promise in medical devices, skin grafts, drug delivery devices, and cellular
scaffolds. (16-21) Unlike the fibers, films don’t need to be woven together after
processing, to make the functional products. Thus, spider silk films are cost effective,
compared to fiber products. rSSP-based films are produced by simply formulating and
pouring a dope, which can easily be modified by changing the formulation to have
increased cell attachment, drug release, and mechanical properties. (20, 22-24)
rSSP are insoluble in aqueous solutions, and conventionally they are dissolved in
1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) to generate dopes to create fibers, films, gels,
and foams. (25-28) However, HFIP residues carry risk to human health and to the
environment; and moreover, HFIP is not a cost-effective way to dissolve rSSP. Recently,
a simple microwave method has been introduced to dissolve rSSPs in aqueous solution,
replacing HFIP, which is not only cost-effective but also addresses the human health
issue as well as environmental concerns. (29)
Alkoxysilanes are often used as the precursor for silicone, a widely used adhesive
to bridge inorganic materials with organic molecules. (30) Hydrolyzed nPM (HnPM)
have shown their ability to induce the secondary structures of the protein and increase the
β-sheets. (31) Thus, we hypothesized that nPM-induced rSSP in aqueous solution can
generate spider silk films with higher surface properties. In this study, we attempted to
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modulate the secondary structure of rSSP by HnPM in aqueous system and investigate
the possible improvement in surface properties of silane-modulated rSSP films.

7.3 Experimental procedure
Materials
n-propyltrimethoxy silane (nPM, > 95 % purity, MW = 164.3, d = 0.94 g/ml) was
purchased from Gelest, Inc. (Morrisville, PA); and 50 % (w/w) NH4OH was purchased
from Fisher Scientific. Muscovite mica was purchased from SPI supplies for the AFM
study (PA, USA); and AFM tips were obtained from TED Pella Inc., CA (TAP300AL-G50). Two different types of rSSP protein, major ampullate silk protein rMaSp1 and major
ampullate silk protein rMaSp2, were purified from the milk of transgenic goats through
tangential flow filtration, precipitation, and washing.
Forming spider silk films
The mold for the water-based films was made from a polydimethylsiloxane
PDMS (Dow Corning) solution of 10:1 base to initiator, and poured into a 90 mm Petri
dish to an approximately 1 mm thickness. The Petri dish and solution was then placed
into a vacuum chamber for 20 min to remove all bubbles. They were then placed in an
oven at 70 °C to cross-link overnight. The solidified PDMS was removed and cut using a
forceps and a razor blade to four 30 × 7 mm strips. The mold was then thoroughly
cleaned using soap and water, followed by isopropanol (IPA). 5 % (w/v) rSSPs were
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dissolved in aqueous solution with or without the presence of HnPM (0.4 M). The
dissolved spider silk solutions were then poured on PDMS structures and dried overnight
at room temperature.
Characterization of silane-modulated spider silk films
The water contact angle was measured with a VCA optima digital contact angle
instrument (AST products, Billerica, MA); on the surface of the films using 10 µl sessile
drops of DI water. AFM images were taken to find the possible change in the silanemodulated spider silk films, compared to spider silk films. AFM images were taken using
a Nanoscope III Bioscope (Digital Instrument, Inc.) in tapping mode. 100 µl samples
were dropped on freshly cleaved mica surfaces, then gently washed with DI water, and
air-dried before taking AFM images.
Both types of films were analyzed with FTIR, using a Varian 660-IR with a
horizontal single reflection Pike Technologies MIRacle attenuated total reflectance
(ATR) unit, fitted with a ZnSe crystal. 100 µl samples were drop cast on the ZnSe crystal
of the ATR platform, and air-dried before taking the reading. Readings were taken after
averaging 20 scans over the range of 600 cm-1 to 1800 cm-1 with a resolution of 1 cm-1.
Prior to each reading, a background scan was acquired.

7.4 Result and Discussion
The static water contact angles on rSSP film and nPM-modulated rSSP film are

163
shown in Figure 7-1 (a) and (b), respectively. Water contact angle on nPM-modulated
rSSPs films was 98±2°, compared to 82±2° on the rSSP films. This increase in contact
angle implies that silane modulation has improved the hydrophobicity of the rSSP films.
The silane modulation increased the % of sheet structures in rSSP, which eventually
improved the hydrophobicity of their films.

Figure 7-1. Static water contact angle on (a) rSSP film and (b) nPM-modulated rSSP
film.
The ATR-FTIR spectrum of nPM-modulated rSSP film showed a shift towards
the β structures (> 1660 cm-1) in the amide I zone (Figure 7-2), compared to the spectrum
of the unmodulated film. Also, the intensity of the peak around 1655-1660 cm-1
increased, which could be due to the increase in sheet structures in rSSP. The increase of
intensity at the CH3- CH2- bending vibration region (1300-1450 cm-1) further confirmed
the silane modulation in the rSSP film.
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Figure 7-2. ATR-FTIR spectra of rSSP and nPM-modulated rSSP film.
AFM images of rSSP and nPM-modulated rSSP films, along with corresponding
height profiles on the surfaces, are shown in Figure 7-3. Silane modulation increased the
surface roughness of the film, as RMS roughness values were 5.23 nm and 9.83 nm on
the rSSP and on the nPM-modulated rSSP film, respectively. This increase in surface
roughness indicates that the adhesive property of the rSSP film was enhanced by the nPM
modulation. (32)
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Figure 7-3. AFM images of (a) rSSP films, and (b) nPM-modulated rSSP film, with the
corresponding cross-sectional height profiles.
7.5 Conclusion
Hydrophobic silane (nPM) enhanced the surface properties of rSSP-based films
by inducing their secondary structures in an aqueous system. Increased hydrophobicity
was confirmed, as the water contact angle on the nPM-modulated rSSP film was higher.
The increased surface roughness on the silane-modulated films can lead to improving the
quality of the rSSP films for various applications, such as adhesion of biological cells on
the surface.
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CHAPTER 8
CONCLUSION

This research contributes to the broader understanding of the silane modulation of
protein secondary structure and self-assembly for developing nanotherapeutic agents to
be used against amyloid-based diseases. The various diseases resulting from protein
pathogenesis include such widely known neurological diseases as Alzheimer’s,
Parkinson’s, and ALS, as well as numerous other diseases such as dialysis-related
amyloidosis and cataracts. The protein-conformation activity of silanes allows for
additional applications in bioprocessing, where they could be applied as artificial
chaperones for disaggregation and refolding of recombinant proteins expressed in
bacteria and yeast. Multi-level functionality can be imparted in the silane-based NPs, as
the present research also shows promise of developing versatile silica-based drugcarrying NPs, which could carry small-molecule therapeutics against amyloid disease in
parallel to the activity exhibited by the fluoro-silane nanoparticle carrier.
Toward the development of NP-therapeutics / drug carriers, this research
characterized methods to tune the silane sol-gel kinetics under aqueous conditions, to
avoid the use of solvents, and to provide a green-chemistry approach to product
synthesis. The hydrolysis and condensation study provides detailed understanding of the
fluoro- and alkoxysilanes, 3F and nPM, respectively. The formation of monodisperse,
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spherical NPs was attainable for 3F, whereas the nPM particles exhibited greater
disparity in size and morphology. The formation of NPs directly from these tri-ethoxy
silanes represents a unique approach to synthesizing functional silane NPs, which
normally proceed via a two-step process in which silica NPs are first created from a tetraethoxy silane precursory (TEOS), followed by surface functionalization with additional
silanes.
Due to the poor solubility of silanes in aqueous solution, established procedures
employ alcohol / water mixtures; however, as shown in this thesis research, an aqueous
synthesis approach can be used by careful selection of pH and silane concentration. The
geometry of the reaction vessel must also be considered, as the silanes form a lens either
at the air / water interface or the bottom of the reaction container for nPM and 3F,
respectively. The ability of the lens to spread and increase the surface area exposed to the
acid solution will influence the hydrolysis reaction rate. Sonication can be employed to
form droplets of silane in the solution, but it does not allow for the in-situ monitoring of
the sol-gel kinetics, as was done here using dynamic light scattering (DLS) and turbidity
scans.
From the hydrolysis and condensation kinetics profiles of 3F and nPM, it was
possible to know exactly when to isolate the polymeric NPs as they evolved for a given
pH, and introduce them to the protein fibrillation reaction, to test their activity. A broader
understanding of the physiological properties of these silane-based NPs is necessary to
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optimize their performance toward fibrillation inhibition processes in more complex, e.g.
multi-protein, environments.
From the model systems investigated in this research, 3F-based silica NPs showed
greater activity against the amyloid fibril inhibition. The research showed that 3F silane
chemistry completely inhibited the amyloid formation against the model protein, BLG, as
evidenced by an absence of fibrils during AFM imaging. Deconvoluted ATR-FTIR
spectra further confirmed the induction of secondary structural motifs in BLG by the
NPs. In particular, 3F-BLG interaction reduced b-sheet content as the silane and BLG
were heated under conditions that normally induced BLG fibrillation. This reduction of
b-sheet content is particularly relevant to amyloid assembly that frequently occurs
through self-assembly of protein monomers via exposed b-sheet motifs.
Molecular docking studies further confirmed the interaction between silanol and
BLG as mediated by hydrogen bonding, involving an unreacted silanol group as a
hydrogen bond donor. The importance of a free silanol moiety in conjunction with the trifluoro or methyl groups of 3F and nPM, respectively, highlights the multi-valent
interaction of these silanes with the protein, in order to influence the protein secondary
structure and fibrillation propensity.
Additional applications of the 3F and nPM particles were also investigated in this
thesis. In particular, NP assembly on surfaces to form super-hydrophobic coatings was
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demonstrated through water contact angle analysis. NP synthesis in a very facile and
environmentally friendly way is an outcome of this research.
In summary, the completed research has demonstrated a unique assembly of trifunctional silanes to form NPs, which is in contrast to the two-step methods commonly
employed. This fluoro-functionality, in conjunction with the unreacted silanol group,
interacted through hydrogen bonding with BLG, inhibiting its fibrillation. In contrast, the
alkyl-presenting silane NPs did not demonstrate significant anti-fibrillation activity.
Ongoing work is investigating the generality of this NP-protein interaction. Loading of
these silica NPs with additional small-molecule therapeutics is feasible, as was
demonstrated using curcumin and quercetin, thus providing a multi-functional NP that
has inherent biological activity and ability to deliver and release additional therapies.
Surface modification with the NPs is a final application to construct superhydrophobic
coatings.
Our extended study on the applications of the fluorinated and methylated
polymeric NPs against the spider silk protein produced enhanced characteristics of their
films. Our study also showed that these polymeric particles can create new
nanocomposites of silica-spider silk protein, which have potential in biomaterials
applications where the silane not only imparts hydrophobic character to the resulting
composite, but also tunes the secondary structure of the resulting composite. Future work
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will explore methods to optimize bulk mechanical properties as well as the observed
surface property changes reported here.
From the engineering perspective, this research offers several engineering aspects:
1. Downstream processing applications, such as disaggregation of recombinant spider
silk proteins that overexpressed and form inclusion bodies.
2. Materials science applications as superhydrophobic nanoparticle surface modifying
agents.
3. Nanocomposite materials: hybrid silica-protein structures are formed that may exhibit
unique biological activity.
4. The one-step aqueous synthesis process is an economically and environmentally
viable approach to scaling this technology for superhydrophobic nanoparticle
production.
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CHAPTER 9
FUTURE WORK
AMYLOID FIBRILS-MESOPOROUS SILICA-BASED HYBRID MEMBRANE FOR
PURIFYING ARSENIC-CONTAMINATED WATER

Introduction
Arsenic is one of the most harmful water pollutants and a major environmental
concern. Dissolved arsenic in ground water affects the health of millions of people all
around the world. (1-2) The human body gets exposed to arsenic through consumption of
contaminated water, which leads to arsenicosis. (3) In natural ground water and surface
water, arsenic is found as neutrally charged arsenite (As (III)) and negatively charged
arsenate (As (V)) oxyanions, depending on pH, redox potential (Eh), and existence of
other chemical species. (4) Several technologies have been explored for removing arsenic
from contaminated water, such as oxidation / precipitation, (5) coagulation, (6)
membrane, (7, 8) ion- exchange, (9, 10) and sorbent technologies. (11-13) A recent study
showed that low-cost milk protein b-lactoglobulin (BLG)-based amyloid fibrils are
highly efficient against arsenic species, along with various heavy metal ions and nuclear
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wastes, where amyloid fibrils interact with water pollutants via strong supramolecular
metal-ligand bonding. (14) The major challenges to use the BLG amyloid fibrils in the
water-purifying membrane are their water-impervious characteristics. One way to
overcome this issue is to create a porous amyloid fibril-based hybrid membrane system,
through which the targeted aqueous media can easily pass. In general, incorporation of
amyloid fibrils with porous hydrophilic materials to create a hybrid membrane will be an
ideal system for addressing this issue.
In a hybrid membrane system, efficiency of these fibrils to interact with the target
pollutants in the water system will depend on their exposed surface area. Tuning the right
amount of fibrils with appropriate hydrophilic porous materials can provide the optimum
available reactive surface area for pollutants to interact with amino acids of the protein. A
comprehensive study on developing a hybrid membrane system by integrating various
types of amyloid fibrils and suitable support materials could lead to creating a highly
efficient membrane for purifying contaminated water.
Mesoporous silica particles (MSP) are widely used for various purposes such as
supports for adsorption, catalysis, chemical separations, biotechnology devices, carrier
for drugs, and components in nanocomposite materials, due to their chemical and thermal
stability and easy functionalization properties. (15-20) In the last few years, we have
investigated the formation of the amyloid fibrils of different proteins such as BLG,
lysozyme (LYS), and spider silk protein (SSP), using conventional heating systems and
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microwave system. We also have investigated the interaction of silica-based NPs with the
amyloid fibrils, and formation of composite materials, which we have presented at
several national and regional conferences. (21-24) Our findings suggest that highly
efficient hybrid membrane systems can be achieved by incorporating amyloid fibrils with
silica-based particles, which could be used to remove the pollutants from contaminated
water.
In a hydrophilic MSP and amyloid fibril hybrid membrane system, the particle
surface properties control the curvature of the amyloid fibrils attached on it, which
eventually determines the availability of the fibrils to the targeted pollutants. Here, we are
proposing an experimental investigation of developing hybrid membrane systems by
incorporating amyloid fibrils and MSP, and use them to purify arsenic-contaminated
water.
Amyloid fibrils bond with water pollutants like arsenic through the amino acids
present in the associated protein monomer. The amino acid number and type in the used
protein will dictate the pollutant-fibril interactions. Since BLG, LYS, and SSP all consist
of different types and numbers of amino acids, their fibrils should behave distinctively on
bonding with arsenic species. These proteins are distinct in their surface charges at
neutral pH, which also could affect their interaction with the silica particles. Therefore,
the protein types and the surface charge of the silica particles (SP) will decide the success
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of the hybrid membrane formation and their efficiency to remove pollutants like arsenic.
Objectives of the proposed research are:
1. To develop a hybrid composite membrane using negatively charged MSP and
amyloid fibrils of three types of protein such as BLG, LYS, and SSP having
negative, positive, and negative surface charges on their surfaces respectively
at neutral pH
2. Use these hybrid membranes to investigate their efficiency to remove the
arsenic species (As (III) and As (V)) from the contaminated water.

Experimental method
Amyloid fibril formation
BLG and LYS will be fibrillated in an acidic aqueous system (pH 2.0) by heating
at 90°C for 5 h for BLG and 60°C for 5 h for LYS in glass vials. For SSP, fibrillation will
be performed using microwave pulse technique, where SSP will be dissolved and
fibrillated in aqueous media at neutral pH by microwaving samples in tightly closed glass
vials for 10 seconds, which will increase the temperature up to 130°C, and then resting
for 1 min; then again 10 seconds of microwaving; and this cycle will be repeated 5 times.
The fibrillation process will be stopped using an ice bath. AFM will be used to confirm
the fibril formation. Figure 9-1 shows the schematic of the fibril formation of different
proteins.
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Figure 9-1. Schematic of the fibril formation process of BLG, LYS, and SSP.
MSP synthesis
MSP will be synthesized following a modified Stöber method, as described in
Figure 9-2. Appropriate mole ratio of ETOH, water, CTAB
(Cetyltrimethylammonium bromide), and TEOS (Tetraethylorthosilicate) will be heated
at 80°C together for 2 h, to generate silica particles with CTAB integrated inside. After
centrifugation, the silica particles will be washed with ETOH, and then CTAB will be
removed by adding a HCl and ETOH mix solution and heating at 60°C for 6 h. Thus, we
will obtain negatively charged MSP, which we will collect after centrifugation and
ETOH wash. To achieve positively charged MSP, we will add APTES ((3-Aminopropyl)
triethoxysilane) in the negatively charged MSP in ETOH solution; and heating at 80°C
for 12 h will give us positively charged MSP. After centrifugation and ETOH wash, we
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will obtain MSP, and SEM images will be taken to confirm the sizes and porosities of the
overnight freeze-dried samples.

Figure 9-2. Synthesis of MSP.
Interacting MSP with amyloid fibrils
Dried MSP with three different sizes from two types will be added to the amyloid
fibrils of BLG, LYS, and SSP protein-containing solutions, as shown in Figure 9-3.
Depending on the surface properties and size of the fibrils and MSP, the interaction will
vary.
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Figure 9-3. Schematic of the possible interactions of amyloid fibril and MSP.
These mixed solutions of MSP and amyloid fibrils will be passed through a
cellulose filter using vacuum filtration. (Figure 9-4) This cellulose filter will hold the
hybrid membrane consisting of amyloid fibrils and MSP.

182
Arsenic contaminated H2O

!" +"
!" !"
!" +"
!" !"
!"+"!" +" +"!"
!"+" +" !"
!" +"+"!" !"!"!" !" !" !"+" !" !"+"
+" !" !" !"
+"!" +" !"!" +"
+"!"+" +"!" !"!"+" +"!"+"+" !"
!"+"
!" +"
!" +"!" +"!"
!" !"
!" !"+"!"!"!"+"!"+"
!" !"+"+"!"!"!" !"!"!" !" !"+"!"!"+"!" +"!"
!"+"!" +" +"!" !" +"
!"
+"!"!" +" !"!" +"
!" +"!"!"!"+" !"!"+" !"+"
!" +"+"!" !"!"!" !"+"
!" !"
!"
!" !" !" +"!"+"
!"+" !" !"+"!"+"
+"!" +" !"!" +"
!"+" !"!"+"!"+"!" +"+"!" !"+"!"
+"!"+" !"+"!" +"!"!"!"+"!" !" +"!"+"+"
!"
!"+"
!"
!"
!"
+"
!"
+" !" !"
+"!"!" !"!"
!" +"
!" !"+"!"!"+"!"+"!" +"
!" +"!" +" !"!" +"
!" +"!"+"
!"!" !"!"!" +"!" !"+"!"!"+"!" +"
!" !"
!" +"
!" !"!"+"!"!"+"!"+" !"!"+"!" !" +"!"!"+"+"!" +"+" +"!"
!" !" +"!" +"
!"+" !" !"
!" !"!"
!"
!"+"!" +" +"!"!"+" !"+"!"+"+"!" !"!"+"+"
!" !"+"!"!" +"!"!" +"!"!" !" !" !"
+" +"
!" +"+"!" !"!"!" !" !"+"!"!"!"+"!"+"!"!"+"!"!"!"+"!"+"
+"!" +" !"
+"!" !"+"+"!" !"!"+"!" !"
+"!" +" !"!"
+"
+"
!"
+"!" +"!"!"!" +"
+"
!" !"!"
!"+"
!" !"+"!"!"+"!" +"!"
!"+" !"+" +"!"+"!" !"+"!"+"+" !" +"
!"
!" !"+" !"+"!"!"+"!"+"
!"+"!" !" !"+"!"!" !"
!"!" !"!" !" !"+"!"!"!"!"+"
+"
!" !" !"+" +"
+" !" !" +"!"!" !"+"!"!" !"
!"
+"!" !"
!" +"+"!" !"!"!" !"
+"
!"+"
+"!" +" !"
!" !"+" !"+"!" +"!"
+"
!"+"
!"
!" !"
!" !"+" !"+"!" +"!"
!"
!" !"

Amyloid fibrils-SiO2 hybrid membrane

Purified H2O

Figure 9-4. Water purification using hybrid membranes in a vacuum filter system.
Purification of arsenic-contaminated water
In the final step, pollutant water containing As (III) and As (V) will be passed
through the hybrid membranes, using a vacuum pump, so the arsenic gets trapped in the
membrane system, and purified water is stored in the flask. (Figure 9-4) The quantity of
the As (III) and As (V) amount in the aqueous system will be measured using AAS
(atomic adsorption spectroscopy).
Expected results
We have already generated amyloid fibrils of BLG, LYS, and SSP. In Figure 9-5,
an AFM image shows the BLG-based amyloid fibrils with different sizes ranging from <1
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µm to >5 µm. We have also synthesized silica-based particles, as shown in Figure 9-6,
where an SEM image shows the silica particles with different sizes, ranging from 0.1 µm
to 0.5 µm.

Figure 9-5. AFM image of amyloid fibrils of BLG (bar is 2µm).

Figure 9-6. SEM image of silica particles.
Following the conventional Stöber method, MSP with different sizes will be
synthesized. Incorporating amyloid fibrils and these MSPs will give us the optimum
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hybrid membrane system, where arsenic-contaminated water will be purified. In this
hybrid membrane system, we are expecting both As (III) and As (V) to be removed
below 10 ppb in the purified aqueous body. Along with As (III) and As (V), other
common water pollutants such as chromium, phosphates, etc. will also be removed from
the contaminated water, to establish the efficiency of our developed membrane system.
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